Document:

EX-10.4

 Exhibit 10.4 

SUBSCRIPTION AGREEMENT 
 This Subscription
Agreement (this “Agreement”) has been executed by the purchaser set forth on the signature page hereof (the “Purchaser”) in connection with the private placement offering (the
“Offering”) by Valeritas Holdings, Inc. (f/k/a Cleaner Yoga Mat, Inc.), a Delaware corporation (the “Company”), of a minimum of $25,000,000 (the “Minimum Offering”) and a
maximum of $40,000,000 (the “Maximum Offering”) of shares (the “Shares”) of the Company’s common stock, par value $[0.001] per share (“Common Stock”), issued, at a purchase
price of $5.00 per Share (the “Purchase Price”), plus up to an additional $10,000,000 of Shares at the Purchase Price to cover over-subscriptions (the “Over-Subscription Option”). This subscription is
being submitted to you in accordance with and subject to the terms and conditions described in this Agreement, the Confidential and Non-Binding Summary Term Sheet of the Company dated April 18, 2016, relating to the Offering (as the same may be
amended or supplemented, the “Term Sheet”), and any other Disclosure Materials (as defined below). The minimum subscription is $50,000 (10,000 Shares). The Company may accept subscriptions for less than $50,000 in
its sole discretion. 
 The Shares being subscribed for pursuant to this Agreement have not been registered under the Securities Act of 1933, as amended
(the “Securities Act”). The Offering is being made on a reasonable best efforts basis to “accredited investors,” as defined in Regulation D (“Regulation D”) as promulgated by the United
States Securities and Exchange Commission (the “SEC”) under the Securities Act in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of
Regulation D. 
 The Shares are being offered and sold in connection with a reverse triangular merger (the “Merger”) between a
wholly-owned subsidiary of the Company and Valeritas, Inc., a Delaware corporation (“Valeritas”), and certain other transactions, on the terms and conditions described in the Term Sheet, pursuant to which Valeritas will
become a wholly-owned subsidiary of the Company, and all of the outstanding capital stock of Valeritas will be cancelled in exchange for shares of the Company’s Common Stock (“Merger Shares”), and the outstanding
Valeritas stock options and warrants will be assumed and converted into the right to receive Common Stock of the Company at the same ratio at which shares of outstanding Valeritas capital stock are exchanged, as further described in the Term Sheet.

 Contemporaneously with the execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration Rights Agreement,
substantially in the form attached as Exhibit A hereto (the “Registration Rights Agreement”), pursuant to which, among other things, the Company agrees to provide certain registration rights with respect to the Shares,
the shares of Common Stock underlying the Placement Agent Warrants (as such term is defined below) (the “Underlying Shares”), shares of Common Stock held by certain pre-Merger stockholders and Merger Shares, under the
Securities Act and the rules and regulations promulgated thereunder and applicable state securities laws. 
 Each closing of the Offering (a
“Closing,” and the date on which such Closing occurs hereinafter referred to as the “Closing Date”) shall take place at the offices of CKR Law LLP, at 1330 Avenue of the Americas, New York, New York
10019 (or such other place as is mutually agreed to by the Company and the Placement Agents (as defined below)). The closing of the Merger and at least the Minimum Offering is anticipated on or before April 29, 2016 (the “Initial Closing
Date”). If the Initial Closing Date occurs on or before April 29, 2016, stockholders of Valeritas prior to the Merger (the “Pre-Merger Stockholders”) shall purchase a minimum aggregate amount of $20,000,000 of
the Offering. If the Initial Closing Date occurs after April 29, 2016, the Pre-Merger Stockholders shall purchase a minimum aggregate amount of $15,000,000 of the Offering; provided, however, that the Pre-Merger Stockholders shall purchase a
sufficient amount of the Over-Subscription Option so that the Pre-Merger Stockholders shall have purchased a minimum aggregate amount of $20,000,000 of the Maximum Offering, if applicable. 

 Any subsequent closing in connection with the Offering will occur, in the Company’s sole discretion, and
without notice to any Purchaser, past, current or prospective, within thirty (30) days of the Initial Closing Date, including the closing of the Over-Subscription Option, if exercised in whole or in part (each, a “Subsequent
Closing”). 
 The Initial Closing will not occur unless: 
  

	 	a.	funds deposited in escrow as described in Section 2b below equal at least the Minimum Offering, and corresponding documentation with respect to such amounts has been delivered by Purchasers as described in
Section 2a below; 

  

	 	b.	the Merger and the related split-off transaction shall have been effected or is simultaneously effected; 

  

	 	c.	Valeritas’ debt conversion and restructuring as described in Schedule 4c shall have been completed; and 

  

	 	d.	the other conditions set forth in Sections 7 and 8 shall have been satisfied. 

 The Term Sheet
and any supplement or amendment thereto, and any disclosure schedule or other information document, delivered to the Purchaser prior to Purchaser’s execution of this Agreement, and any such document delivered to the Purchaser after
Purchaser’s execution of this Agreement and prior to the Closing of the Purchaser’s subscription hereunder (including, without limitation, a substantially complete draft of the Current Report on Form 8-K describing the Merger, the Offering
and the related transactions, including “Form 10 information” (as defined in Rule 144(i)(3) under the Securities Act), to be filed by the Company with the SEC within four (4) Business Days after the closing of the Merger and the Initial
Closing of the Offering (the “Super 8-K”), are collectively referred to as the “Disclosure Materials.” For purposes of this Agreement, “Business Day” means a day, other than a
Saturday or Sunday, on which banks in New York City are open for the general transaction of business. 
  

	 	1.	Subscription. The undersigned Purchaser hereby subscribes to purchase the number of Shares set forth on the Omnibus Signature Page attached hereto, for the aggregate Purchase Price as set forth on such
Omnibus Signature Page, subject to the terms and conditions of this Agreement and on the basis of the representations, warranties, covenants and agreements contained herein. 

 

	 	2.	Subscription Procedure. To complete a subscription for the Shares, the Purchaser must fully comply with the subscription procedure provided in paragraphs a. through c. of this Section on or before the
Closing Date. 

  

	 	a.	Subscription Documents. On or before the Closing Date, the Purchaser shall review, complete and execute the Omnibus Signature Page to this Agreement and the Registration Rights Agreement, Investor Profile,
Anti-Money Laundering Form and Investor Certification, attached hereto following the Omnibus Signature Page (collectively, the “Subscription Documents”), and deliver the Subscription Documents to CKR Law LLP
(“CKR”), at the address set forth under the caption “How to subscribe for Shares in the private offering of Valeritas Holdings, Inc.” attached hereto as Annex A. Executed documents
may be delivered to CKR by facsimile or .pdf sent by electronic mail (e-mail), if the Purchaser delivers the original copies of the documents to CKR as soon as practicable thereafter. 

  
 2 

	 	b.	Purchase Price. Simultaneously with the delivery of the Subscription Documents to CKR as provided herein, and in any event on or prior to the Closing Date, the Purchaser shall deliver to Delaware Trust Company,
in its capacity as escrow agent (the “Escrow Agent”), the full Purchase Price by certified or other bank check or by wire transfer of immediately available funds, pursuant to the instructions set forth under the caption
“How to subscribe for Shares in the private offering of Valeritas Holdings, Inc.” attached hereto as Annex A. Such funds will be held for the Purchaser’s benefit in the escrow account established for the Offering
(the “Escrow Account”) and will be returned promptly, without interest or offset, if this Agreement is not accepted by the Company or the Offering is terminated pursuant to its terms by the Company prior to the Closing.

  

	 	c.	Company Discretion. The Purchaser understands and agrees that the Company in its sole discretion reserves the right to accept or reject this or any other subscription for Shares, in whole or in part,
notwithstanding prior receipt by the Purchaser of notice of acceptance of this subscription. The Company shall have no obligation hereunder until the Company shall execute and deliver to the Purchaser an executed copy of this Agreement. If
this subscription is rejected in whole, or the Offering is terminated, all funds received from the Purchaser will be returned without interest or offset, and this Agreement shall thereafter be of no further force or effect. If this subscription
is rejected in part, the funds for the rejected portion of this subscription will be returned without interest or offset, and this Agreement will continue in full force and effect to the extent this subscription was accepted. 

 

	 	3.	Placement Agents. 

  

	 	a.	Wedbush Securities, Inc. (“Wedbush”), Roth Capital Partners, LLC (“Roth”) and Katalyst Securities LLC (“Katalyst”), each a broker-dealer licensed
with the Financial Industry Regulatory Authority, Inc. (“FINRA”), have been engaged on a co-exclusive basis as placement agents (the “Placement Agents”), with Wedbush acting as the lead Placement Agent, for
the Offering on a reasonable best efforts basis. The Placement Agents will be paid at each Closing an aggregate cash commission of eight percent (8%) of gross proceeds raised from investors in the Offering introduced by them (“Cash
Fee”) and will receive warrants to purchase an aggregate number of shares of Common Stock equal to eight percent (8%) of the number of Shares sold to the investors in the Offering introduced by the Placement Agents, with a term of five
(5) years from the Initial Closing Date or any Subsequent Closing, as applicable, and an exercise price of $5.00 per share (the “Placement Agent Warrants”); provided, however, that funds raised from certain existing
shareholders of Valeritas will be subject to a Cash Fee of one percent (1%) and will have no Placement Agent Warrants coverage. 

  

	 	b.	The Placement Agent Warrants will have “weighted average” anti-dilution protection, subject to customary exceptions. Any sub-agent of a Placement Agent that introduces investors to the Offering will be
entitled to share in the Cash Fees and/or Placement Agent Warrants attributable to those investors, pursuant to the terms of an executed sub-agent agreement. 

  

	 	c.	The Company will pay certain expenses of the Placement Agents in connection with the Offering. 

  
 3 

	 	4.	Representations and Warranties of the Company. Except as set forth on the Disclosure Schedule delivered to the Purchasers concurrently with the execution of this Agreement, the Company hereby represents and
warrants to the Purchaser, as of the Initial Closing Date and after giving effect to the Merger (unless otherwise specified) and as of each Subsequent Closing, the following: 

 

	 	a.	Organization and Qualification. The Company and each of its subsidiaries is a corporation or other business entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its
formation, and has the requisite corporate power to own its properties and to carry on its business as now being conducted. The Company and each of its subsidiaries is duly qualified as a foreign corporation to do business and is in good standing in
every jurisdiction in which the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the assets,
business, conditions (financial or otherwise), results of operations or future prospects of the Company and its subsidiaries taken as a whole (a “Material Adverse Effect”). Each subsidiary of the Company is identified on
Schedule 4a attached hereto. 

  

	 	b.	Authorization, Enforcement, Compliance with Other Instruments. (i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement, the Registration
Rights Agreement, the Escrow Agreement and each of the other agreements and documents that are exhibits hereto or thereto or are contemplated hereby or thereby or necessary or desirable to effect the transactions contemplated hereby or thereby (the
“Transaction Documents”) and to issue the Shares, in accordance with the terms hereof and thereof; (ii) the execution and delivery by the Company of each of the Transaction Documents and the consummation by it of the transactions
contemplated hereby and thereby, including, without limitation, the issuance of the Shares, have been, or will be at the time of execution of such Transaction Document, duly authorized by the Company’s Board of Directors, and no further consent
or authorization is, or will be at the time of execution of such Transaction Document, required by the Company, its respective Board of Directors or its stockholders; (iii) each of the Transaction Documents will be duly executed and delivered by the
Company; and (iv) the Transaction Documents when executed will constitute the valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability may be limited by general
principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies. 

 

	 	c.	 Capitalization. The authorized capital stock of the Company consists of 300,000,000 shares of Common Stock
and 10,000,000 shares of preferred stock. Immediately before giving effect to the Merger and the initial Closing of the Offering, the Company has 1,000,000 shares of Common Stock and no preferred stock issued and outstanding. All of the outstanding
shares of Common Stock and of the stock of each of the Company’s subsidiaries have been duly authorized, validly issued and are fully paid and nonassessable. Immediately after giving effect to the Merger and the Closing of the Minimum Offering
or the Maximum Offering plus the Over-Subscription Option, the pro forma outstanding capitalization of the Company will be as set forth under “Pro Forma Capitalization” in Schedule 4c. After giving effect to the
Merger: (i) no shares of capital stock of the Company or any of its subsidiaries will be subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company; (ii) except as set forth on
Schedule 4c(ii) there will be no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the
Company or any of its subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its
subsidiaries; (iii) there 

  
 4 

	 	
will be no outstanding debt securities other than indebtedness as set forth in Schedule 4c(iii); (iv) other than pursuant to the Registration Rights Agreement or as set forth
in Schedule 4c(iv), there will be no agreements or arrangements under which the Company or any of its subsidiaries is obligated to register the sale of any of their securities under the Securities Act;
(v) there will be no outstanding registration statements, and there will be no outstanding comment letters from the SEC or any other regulatory agency; (vi) except as provided in this Agreement or as set forth in Schedule 4c(vi),
there will be no securities or instruments containing anti-dilution or similar provisions, including the right to adjust the exercise, exchange or reset price under such securities, that will be triggered by the issuance of the Shares as described
in this Agreement; and (vii) no co-sale right, right of first refusal or other similar right will exist with respect to the Shares or the issuance and sale thereof. Upon request, the Company will make available to the Purchaser true and correct
copies of the Company’s Certificate of Incorporation, as in effect as of the date hereof (the “Certificate of Incorporation”), and the Company’s By-laws, as in effect as of the date hereof (the
“By-laws”), and the terms of all securities exercisable for Common Stock and the material rights of the holders thereof in respect thereto other than stock options issued to officers, directors, employees and consultants.

  

	 	d.	Issuance of Shares. The Shares are duly authorized and, upon issuance in accordance with the terms hereof, shall be duly issued, fully paid and nonassessable, and are free and clear from all taxes, liens and
charges with respect to the issue thereof. The Underlying Shares have been duly authorized and reserved for issuance and, upon exercise of the Placement Agent Warrants in accordance with their terms, including payment of the exercise price therefor,
will be validly issued, fully paid and nonassessable, and are free and clear from all taxes, liens and charges with respect to the issue thereof. 

  

	 	e.	 No Conflicts. The execution, delivery and performance of each of the Transaction Documents by the
Company, and the consummation by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation of the Certificate of Incorporation or the By-laws (or equivalent constitutive document) of the Company or any of its
subsidiaries or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any subsidiary is a party, except for those which would not reasonably be expected to have a Material Adverse Effect, or (iii) result in a
material violation of any law, rule, regulation, order, judgment or decree (including U.S. federal and state securities laws and regulations) applicable to the Company or any subsidiary or by which any property or asset of the Company or any
subsidiary is bound or affected. Neither the Company nor any of its subsidiaries is in violation of any term of or in default under its Certificate of Incorporation, By-laws or any other constitutive documents. Except for those violations
or defaults which would not reasonably be expected to have a Material Adverse Effect, neither the Company nor any subsidiary is in violation of any term of or in default under any contract, agreement, mortgage, indebtedness, indenture, instrument,
judgment, decree or order or any statute, rule or regulation applicable to the Company or any subsidiary. The business of the Company and its subsidiaries is not being conducted, and shall not be conducted in violation of any law, ordinance or
regulation of any governmental entity, except for any violation which would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Except as specifically contemplated by this Agreement and as required
under the Securities Act and any applicable state securities laws, neither the Company nor any of its subsidiaries is required to obtain any consent, authorization or order of, or make any filing or registration

  
 5 

	 	
with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under or contemplated by this Agreement or the other Transaction Documents in
accordance with the terms hereof or thereof. Except as set forth on Schedule 4e, neither the execution and delivery by the Company of the Transaction Documents, nor the consummation by the Company of the transactions contemplated
hereby or thereby, will require any notice, consent or waiver under any contract or instrument to which the Company or any subsidiary is a party or by which the Company or any subsidiary is bound or to which any of their assets is subject. All
consents, authorizations, orders, filings and registrations which the Company or any of its subsidiaries is required to obtain pursuant to the preceding two sentences have been or will be obtained or effected on or prior to the Closing. The
Company is unaware of any facts or circumstance, which might give rise to any of the foregoing. 

  

	 	f.	Absence of Litigation. Except as set forth on Schedule 4f, there is no action, suit, claim, inquiry, notice of violation, proceeding (including any partial proceeding such as a
deposition) or investigation before or by any court, public board, governmental or administrative agency, self-regulatory organization, arbitrator, regulatory authority, stock market, stock exchange or trading facility (an
“Action”) now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries. For the purpose of this Agreement, the knowledge of the Company means the knowledge of the
officers of the Company and Valeritas (both actual or knowledge that they would have had upon reasonable investigation). 

  

	 	g.	Acknowledgment Regarding Purchaser’s Purchase of the Shares. The Company acknowledges and agrees that each Purchaser is acting solely in the capacity of an arm’s length purchaser with respect to the
Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction
Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers’ purchase of the Shares. 

  

	 	h.	No General Solicitation. Neither the Company, nor any of its Affiliates, nor, to the knowledge of the Company, any person acting on its or their behalf, has engaged in any form of general solicitation or
general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Shares. With respect to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by the same investment
manager as such Purchaser will be deemed to be an Affiliate of such Purchaser. For purposes of this Agreement, “Affiliate” means, with respect to any person, any other person that, directly or indirectly through one or
more intermediaries, controls, is controlled by or is under common control with such person, as such terms are used in and construed under Rule 144 under the Securities Act (“Rule 144”). 

 

	 	i.	No Integrated Offering. Neither the Company, nor any of its Affiliates, nor to the knowledge of the Company, any person acting on its or their behalf has, directly or indirectly, made any offers or sales of
any security or solicited any offers to buy any security, under circumstances that would require registration of the Shares under the Securities Act or cause this offering of the Shares to be integrated with prior offerings by the Company for
purposes of the Securities Act. 

  
 6 

	 	j.	Employee Relations. Neither Company nor any subsidiary is involved in any labor dispute nor, to the knowledge of the Company, is any such dispute threatened. Neither Company nor any subsidiary is party to any
collective bargaining agreement. The Company’s and/or its subsidiaries’ employees are not members of any union, and the Company believes that its and its subsidiaries’ relationship with their respective employees is good.

  

	 	k.	 Intellectual Property Rights. Except as set forth on Schedule 4k, the Company and each
of its subsidiaries owns, possesses, or has rights to, all Intellectual Property necessary for the conduct of the Company’s and its subsidiaries’ business as now conducted, except as such failure to own, possess or have such rights would
not reasonably be expected to result in a Material Adverse Effect and (ii) there are no unreleased liens or security interests which have been filed, or which the Company has received notice of, against any of the patents owned or licenses to the
Company. Furthermore, (A) to the Company’s knowledge, there is no infringement, misappropriation or violation by third parties of any such Intellectual Property, except as such infringement, misappropriation or violation would not result in a
Material Adverse Effect; (B) there is no pending or, to the Company’s knowledge, threatened, action, suit, proceeding or claim by others challenging the Company’s or any of its subsidiaries’ rights in or to any such Intellectual
Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (C) the Intellectual Property owned by the Company and its subsidiaries, and to the Company’s knowledge, the Intellectual Property
licensed to the Company and its subsidiaries, has not been adjudged invalid or unenforceable, in whole or in part, and there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the
validity, enforceability or scope of any such Intellectual Property, and, to the Company’s knowledge, there are no facts which would form a reasonable basis for any such claim; (D) there is no pending or, to the Company’s knowledge,
threatened action, suit, proceeding or claim by others that the Company or any of its subsidiaries infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights of others, neither the Company nor any of its
subsidiaries has received any notice of such claim and, to the Company’s knowledge, there are no other facts which would form a reasonable basis for any such claim, except for any action, suit, proceeding or claim as would not be reasonably
expected to have a Material Adverse Effect; and (E) to the Company’s knowledge, no employee of the Company or any of its subsidiaries is in or has ever been in violation of any term of any employment contract, patent disclosure agreement,
invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee’s employment with
the Company or any of its subsidiaries or actions undertaken by the employee while employed with the Company or any of its subsidiaries, except as such violation would not reasonably be expected to have a Material Adverse Effect. Except as would not
reasonably be expected to have a Material Adverse Effect, (A) the Company and its subsidiaries have disclosed to the U.S. Patent and Trademark Office (USPTO) all information known to the Company to be relevant to the patentability of its
inventions in accordance with 37 C.F.R. Section 1.56, and (B) neither the Company nor any of its subsidiaries made any misrepresentation or concealed any information from the USPTO in any of the patents or patent applications owned or licensed to
the Company, or in connection with the prosecution thereof, in violation of 37 C.F.R. Section 1.56. Except as would not reasonably be expected to have a Material Adverse Effect and to the Company’s knowledge, (A) there are no facts that are
reasonably likely to provide a basis for a finding that the Company or any of its subsidiaries does not have clear title or valid license or sublicense rights to the patents or patent applications owned or licensed to the Company or other
proprietary information rights as being owned by, or licensed or sublicensed to, as the case may be, the Company or any of 

  
 7 

	 	
its subsidiaries, (B) no valid issued U.S. patent is or would be infringed by the activities of the Company or any of its subsidiaries relating to products currently or proposed to be
manufactured, used or sold by the Company or any of its subsidiaries and (C) there are no facts with respect to any issued patent owned or licensed to the Company that would cause any claim of any such patent not to be valid and enforceable in
accordance with applicable regulations. “Intellectual Property” shall mean all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade
secrets, domain names, technology and know-how. 

  

	 	l.	Environmental Laws. 

  

	 	(i)	The Company and each subsidiary has complied with all applicable Environmental Laws (as defined below), except for violations of Environmental Laws that, individually or in the aggregate, have not had and would not
reasonably be expected to have a Material Adverse Effect. There is no pending or, to the knowledge of the Company, threatened civil or criminal litigation, notice of violation, formal administrative proceeding, or investigation, inquiry or
information request, relating to any Environmental Law involving the Company or any subsidiary, except for litigation, notices of violations, formal administrative proceedings or investigations, inquiries or information requests that, individually
or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, “Environmental Law” means any national, state, provincial or local law, statute, rule or regulation
or the common law relating to the environment or occupational health and safety, including without limitation any statute, regulation, administrative decision or order pertaining to (i) treatment, storage, disposal, generation and transportation of
industrial, toxic or hazardous materials or substances or solid or hazardous waste; (ii) air, water and noise pollution; (iii) groundwater and soil contamination; (iv) the release or threatened release into the environment of industrial, toxic or
hazardous materials or substances, or solid or hazardous waste, including without limitation emissions, discharges, injections, spills, escapes or dumping of pollutants, contaminants or chemicals; (v) the protection of wild life, marine life and
wetlands, including without limitation all endangered and threatened species; (vi) storage tanks, vessels, containers, abandoned or discarded barrels, and other closed receptacles; (vii) health and safety of employees and other persons; and (viii)
manufacturing, processing, using, distributing, treating, storing, disposing, transporting or handling of materials regulated under any law as pollutants, contaminants, toxic or hazardous materials or substances or oil or petroleum products or solid
or hazardous waste. As used above, the terms “release” and “environment” shall have the meaning set forth in the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended. 

 

	 	(ii)	To the knowledge of the Company, there is no material environmental liability with respect to any solid or hazardous waste transporter or treatment, storage or disposal facility that has been used by the Company or any
subsidiary. 

  

	 	(iii)	The Company and its subsidiaries (i) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses except to the extent that the
failure to have such permits, licenses or other approvals would not have a Material Adverse Effect, and (ii) are in compliance, in all material respects, with all terms and conditions of any such permit, license or approval. 

 

	 	m.	 Authorizations; Regulatory Compliance. The Company and each of its subsidiaries holds, and is
operating in compliance with, all authorizations, licenses, permits, approvals, 

  
 8 

	 	
clearances, registrations, exemptions, consents, certificates and orders of any governmental authority and supplements and amendments thereto (collectively, “Authorizations”) required
for the conduct of its business and all such Authorizations are valid and in full force and effect and neither the Company nor any of its subsidiaries is in material violation of any terms of any such Authorizations, except, in each case, such as
would not reasonably be expected to have a Material Adverse Effect; and neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such Authorization, or has reason to believe that any such
Authorization will not be renewed in the ordinary course, except to the extent that any such revocation, modification, or non-renewal would not be reasonably expected to have a Material Adverse Effect. The Company and each of its subsidiaries is in
compliance with all applicable federal, state, local and foreign laws, regulations, orders and decrees, except as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any
unresolved FDA Form 483, notice of adverse filing, warning letter, untitled letter or other correspondence or notice from the U.S. Food and Drug Administration (“FDA”), or any other federal, state, local, or foreign governmental or
regulatory authority, alleging or asserting noncompliance with the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.). The Company and each of its subsidiaries, and to the Company’s knowledge, each of their respective directors,
officers, employees and agents, is and has been in material compliance with applicable health care laws, including, to the extent applicable, without limitation, the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.), the federal
Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the civil False Claims Act (31 U.S.C. § 3729 et seq.), the criminal False Claims Law (42 U.S.C. § 1320a-7b(a)), the Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a), the Health
Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. § 17921 et seq.), the exclusion laws (42 U.S.C.
§ 1320a-7), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), and the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Affordability Reconciliation
Act of 2010, including without limitation the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), and the regulations promulgated pursuant to such laws, and comparable state laws (collectively, “Health Care Laws”). Neither the
Company nor any of its subsidiaries has received notice of any ongoing claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority or third party alleging that any product
operation or activity is in material violation of any Health Care Laws or Authorizations and has no knowledge that any such Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or
proceeding. Neither the Company nor any of its subsidiaries has received notice that any governmental authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such
governmental authority is considering such action. The Company and each of its subsidiaries has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
thereto as required by any Health Care Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete, correct and not misleading on the date filed
(or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries has, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall,
market withdrawal or replacement, safety alert, post sale warning, “dear doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the
Company’s knowledge, no third party has 

  
 9 

	 	
initiated or conducted any such notice or action. Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreement, deferred prosecution agreement, monitoring
agreement, consent decree, settlement order, or similar agreements, or has any reporting obligations pursuant to any such agreement, plan or correction or other remedial measure entered into with any Governmental Authority. Neither the Company,
its subsidiaries nor their officers, directors, employees, agents or contractors has been or is currently excluded from participation in the Medicare and Medicaid programs or any other state or federal health care program. 

 

	 	n.	Title. Neither the Company nor any of its subsidiaries owns any real property. Except as set forth on Schedule 4n, each of the Company and its subsidiaries has good and marketable title to
all of its personal property and assets, free and clear of any restriction, mortgage, deed of trust, pledge, lien, security interest or other charge, claim or encumbrance which would have a Material Adverse Effect. Except as set forth on
Schedule 4n, with respect to properties and assets it leases, each of the Company and its subsidiaries is in compliance with such leases and holds a valid leasehold interest free of any liens, claims or encumbrances which would have a
Material Adverse Effect. 

  

	 	o.	No Material Restrictions, Breaches, etc. Neither Company nor any subsidiary is subject to any charter, corporate or other legal restriction, or any judgment, decree, order, rule or regulation which in the
judgment of the Company’s officers has had, or is reasonably expected in the future to have, a Material Adverse Effect. Neither Company nor any subsidiary is in breach of any contract or agreement which breach, in the judgment of the
Company’s officers, has had, or is reasonably expected to have a Material Adverse Effect. 

  

	 	p.	Tax Status. The Company and each subsidiary has made and filed (taking into account any valid extensions) all federal and state income and all other tax returns, reports and declarations required by any
jurisdiction to which it is subject and (unless and only to the extent that the Company or such subsidiary has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) has paid all taxes and other
governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set aside on its books provision reasonably adequate for
the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. To the knowledge of the Company, there are no unpaid taxes in any material amount claimed to be due from the Company or any
subsidiary by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim. 

  

	 	q.	Certain Transactions. Except for arm’s length transactions pursuant to which the Company or any subsidiary makes payments in the ordinary course of business upon terms no less favorable than it could obtain
from third parties, none of the officers, directors, or employees of the Company or any subsidiary is a party to any transaction with the Company or any subsidiary (other than for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the
knowledge of the Company, any corporation, partnership, trust or other entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. 

 

	 	r.	Rights of First Refusal. Except as set forth on Schedule 4c(i) or Schedule 4r, the Company is not obligated to offer the securities offered hereunder on a right of first refusal
basis or otherwise to any third parties including, but not limited to, current or former stockholders of the Company, underwriters, brokers, agents or other third parties. 

  
 10 

	 	s.	Insurance. The Company has insurance policies of the type and in amounts customarily carried by organizations conducting businesses or owning assets similar to those of the Company and its
subsidiaries. There is no material claim pending under any such policy as to which coverage has been questioned, denied or disputed by the underwriter of such policy. 

 

	 	t.	SEC Reports. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), including pursuant to Section 15(d) thereof (or that it would have been required to file by Section 15(d) of the Exchange Act if its duty to file thereunder had not been automatically suspended) (collectively, together with the
Super 8-K, the “SEC Reports”) for the two (2) years preceding the date hereof (or such shorter period since the Company was first required by law or regulation to file such material). To the Company’s knowledge, the
draft Super 8-K furnished to each Purchaser prior to the Initial Closing will not materially deviate from the Super 8-K. 

  

	 	u.	Financial Statements. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with
respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with GAAP applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated subsidiaries taken
as a whole as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, year-end audit adjustments. The pro forma financial information and the
related notes, if any, included in the SEC Reports have been properly compiled and prepared in accordance with the applicable requirements of the Securities Act and the regulations promulgated thereunder and fairly present in all material respects
the information shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. 

 

	 	v.	 Material Changes. Since the respective date of the latest balance sheet of the Company and the latest
balance sheet of Valeritas included in the financial statements contained within the SEC Reports, except as specifically disclosed in the SEC Reports, (i) there have been no events, occurrences or developments that have had or would reasonably
be expected to have a Material Adverse Effect with respect to the Company or Valeritas, (ii) neither the Company nor Valeritas has incurred any material liabilities (contingent or otherwise) other than (A) trade payables, accrued expenses
and other liabilities incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the financial statements of the Company or of Valeritas, as applicable, pursuant to GAAP or to
be disclosed in filings made with the SEC, (iii) neither the Company nor Valeritas has materially altered its method of accounting or the manner in which it keeps its accounting books and records, (iv) neither the Company nor Valeritas has
declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock (other than in connection with repurchases of unvested
stock issued to employees of the Company), (v) neither the Company nor Valeritas has issued any equity securities to any officer, director or Affiliate, 

  
 11 

	 	
except Common Stock issued in the ordinary course pursuant to existing Company or Valeritas stock option or stock purchase plans or executive and director corporate arrangements disclosed in the
SEC Reports and Common Stock issued pursuant to the Merger, (vi) there has not been any change or amendment to, or any waiver of any material right under, any material contract under which the Company, Valeritas or any of their assets are bound
or subject, and (vii) except for the issuance of the Shares and Placement Agent Warrants contemplated by this Agreement, no event, liability or development has occurred or exists with respect to the Company, Valeritas or each of their businesses,
properties, operations or financial condition, as applicable, that would be required to be disclosed by the Company or Valeritas under applicable securities laws at the time this representation is made that has not been publicly disclosed in the SEC
Reports. 

  

	 	w.	Transactions With Affiliates and Employees. None of the officers or directors of the Company and, to the Company’s knowledge, none of the employees of the Company, is a party to any transaction with the
Company or to a transaction contemplated by the Company (other than for services as employees, officers and directors) that would be required to be disclosed by the Company pursuant to Item 404 of Regulation S-K promulgated under the Securities Act,
except as contemplated by the Transaction Documents or set forth in the SEC Reports. 

  

	 	x.	Sarbanes-Oxley. The Company is in compliance in all material respects with all of the provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it. 

 

	 	y.	Disclosure Controls. The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-14 and 15d-14 under the Exchange Act) and such controls and procedures are effective in
ensuring that material information relating to the Company, including its subsidiaries, is made known to the principal executive officer and the principal financial officer. 

 

	 	z.	Off-Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company and an unconsolidated or other off-balance sheet entity that is required to be disclosed by the
Company in its SEC Reports (including, for purposes hereof, any that are required to be disclosed in a Form 10) and is not so disclosed or that otherwise would have a Material Adverse Effect. 

 

	 	aa.	Foreign Corrupt Practices. Neither the Company and its subsidiaries, nor to the Company’s knowledge, any agent or other person acting on behalf of the Company and its subsidiaries, has: (i) directly or
indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to
any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company (or made by any person acting on its behalf of which the Company is aware) which is in violation of law
or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. 

  

	 	bb.	Brokers’ Fees. Neither of the Company nor any of its subsidiaries has any liability or obligation to pay any fees or commissions to any broker, finder or agent with respect to the transactions
contemplated by this Agreement, except for the payment of fees to the Placement Agents as described in Section 3 above. 

  
 12 

	 	cc.	Disclosure Materials. The SEC Reports and the Disclosure Materials taken as a whole do not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading. 

  

	 	dd.	Investment Company. The Company is not required to be registered as, and is not an Affiliate of, and immediately following the Closing will not be required to register as, an “investment company” within
the meaning of the Investment Company Act of 1940, as amended. 

  

	 	ee.	Reliance. The Company acknowledges that the Purchaser is relying on the representations and warranties made by the Company hereunder and that such representations and warranties are a material inducement to
the Purchaser purchasing the Shares. The Company further acknowledges that without such representations and warranties of the Company made hereunder, the Purchasers would not enter into this Agreement. 

 

	 	5.	Representations, Warranties and Agreements of the Purchaser. The Purchaser represents and warrants to, and agrees with, the Company the following: 

 

	 	a.	The Purchaser has the knowledge and experience in financial and business matters necessary to evaluate the merits and risks of its prospective investment in the Company, and has carefully reviewed and understands the
risks of, and other considerations relating to, the purchase of Shares and the tax consequences of the investment. 

  

	 	b.	The Purchaser is acquiring the Shares for investment for its own account and not with the view to, or for resale in connection with, any distribution thereof. The Purchaser understands and acknowledges that the
Offering and sale of the Shares have not been registered under the Securities Act or any state securities laws, by reason of a specific exemption from the registration provisions of the Securities Act and applicable state securities laws, which
depends upon, among other things, the bona fide nature of the investment intent as expressed herein. The Purchaser further represents that it does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or
grant participation to any third person with respect to any of the Shares. The Purchaser understands and acknowledges that the offering of the Shares pursuant to this Agreement will not be registered at the time of their acquisition by the
Purchaser, and may never be registered, under the Securities Act nor under the state securities laws on the ground that the sale provided for in this Agreement and the issuance of securities hereunder is exempt from the registration requirements of
the Securities Act and any applicable state securities laws. 

  

	 	c.	The Purchaser is an “accredited investor” as defined in Rule 501 of Regulation D as promulgated by the SEC under the Securities Act, for the reason(s) specified on the Accredited Investor
Certification attached hereto as completed by Purchaser, and Purchaser shall submit to the Company such further assurances of such status as may be reasonably requested by the Company. The Purchaser resides in the jurisdiction set forth on
the Purchaser’s Omnibus Signature Page affixed hereto. 

  

	 	d.	 The Purchaser (i) if a natural person, represents that he or she is the greater of (A) 21 years of age or (B) the
age of legal majority in his or her jurisdiction of residence, and has full power and authority to execute and deliver this Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof; (ii) if a
corporation, partnership, limited liability company or partnership, association, joint stock company, trust, unincorporated organization or other entity, represents that such entity was not formed for the

  
 13 

	 	
specific purpose of acquiring the Shares, such entity is duly organized, validly existing and in good standing under the laws of the state or jurisdiction of its organization, the consummation of
the transactions contemplated hereby is authorized by, and will not result in a violation of state law or its charter or other organizational documents, such entity has full power and authority to execute and deliver this Agreement and all other
related agreements or certificates and to carry out the provisions hereof and thereof and to purchase and hold the Shares, the execution and delivery of this Agreement has been duly authorized by all necessary action, this Agreement has been duly
executed and delivered on behalf of such entity and is a legal, valid and binding obligation of such entity; or (iii) if executing this Agreement in a representative or fiduciary capacity, represents that it has full power and authority to execute
and deliver this Agreement in such capacity and on behalf of the subscribing individual, ward, partnership, trust, estate, corporation, or limited liability company or partnership, or other entity for whom the Purchaser is executing this Agreement,
and such individual, partnership, ward, trust, estate, corporation, or limited liability company or partnership, or other entity has full right and power to perform pursuant to this Agreement and make an investment in the Company, and represents
that this Agreement constitutes a legal, valid and binding obligation of such entity. The execution and delivery of this Agreement will not violate or be in conflict with any order, judgment, injunction, agreement or controlling document to
which the Purchaser is a party or by which it is bound. 

  

	 	e.	The Purchaser understands that the Shares are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is
relying in part upon the truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Purchaser set forth herein in order to determine the availability of
such exemptions and the eligibility of such Purchaser to acquire such securities. The Purchaser further acknowledges and understands that the Company is relying on the representations and warranties made by the Purchaser hereunder and that such
representations and warranties are a material inducement to the Company to sell the Shares to the Purchaser. The Purchaser further acknowledges that without such representations and warranties of the Purchaser made hereunder, the Company would
not enter into this Agreement with the Purchaser. 

  

	 	f.	The Purchaser understands that no public market exists for the Company’s Common Stock and that there can be no assurance that any public market for the Common Stock will exist or continue to exist.

  

	 	g.	 The Purchaser has received and reviewed information about the Company, including all Disclosure Materials, and
has had an opportunity to discuss the Company’s business, management and financial affairs with the Company’s management. The Purchaser understands that such discussions, as well as any Disclosure Materials provided by the Company, were
intended to describe the aspects of the Company’s business and prospects which the Company believes to be material, but were not necessarily a thorough or exhaustive description, and except as expressly set forth in this Agreement, the Company
makes no representation or warranty with respect to the completeness of such information and makes no representation or warranty of any kind with respect to any information provided by any entity other than the Company. Some of such information may
include projections as to the future performance of the Company, which projections may not be realized, may be based on assumptions which may not be correct and may be subject to numerous factors beyond the Company’s control. Additionally, the
Purchaser understands and represents that it is purchasing the Shares notwithstanding the fact that the Company may 

  
 14 

	 	
disclose in the future certain material information the Purchaser has not received, including (without limitation) financial statements of the Company and/or Valeritas for the current or prior
fiscal periods, and any subsequent period financial statements that will be filed with the SEC, that it is not relying on any such information in connection with its purchase of the Shares and that it waives any right of action with respect to the
nondisclosure to it prior to its purchase of the Shares of any such information. Each Purchaser has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its
acquisition of the Shares. 

  

	 	h.	The Purchaser acknowledges that none of the Company or the Placement Agents is acting as a financial advisor or fiduciary of the Purchaser (or in any similar capacity) with respect to the Transaction Documents and the
transactions contemplated hereby and thereby, and no investment advice has been given by the Company, the Placement Agents or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated hereby and thereby. The Purchaser further represents to the Company that the Purchaser’s decision to enter into the Transaction Documents has been based solely on the independent evaluation by the Purchaser and its representatives.

  

	 	i.	As of the Closing, all actions on the part of Purchaser, and its officers, directors and partners, if applicable, necessary for the authorization, execution and delivery of this Agreement and the Registration Rights
Agreement and the performance of all obligations of the Purchaser hereunder and thereunder shall have been taken, and this Agreement and the Registration Rights Agreement, assuming due execution by the parties hereto and thereto, constitute valid
and legally binding obligations of the Purchaser, enforceable in accordance with their respective terms, subject to: (i) judicial principles limiting the availability of specific performance, injunctive relief, and other equitable remedies and (ii)
bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect generally relating to or affecting creditors’ rights. 

  

	 	j.	 Purchaser represents that neither it nor, to its knowledge, any person or entity controlling, controlled by or
under common control with it, nor any person having a beneficial interest in it, nor any person on whose behalf the Purchaser is acting: (i) is a person listed in the Annex to Executive Order No. 13224 (2001) issued by the President of the United
States (Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism); (ii) is named on the List of Specially Designated Nationals and Blocked Persons maintained by the U.S. Office
of Foreign Assets Control; (iii) is a non-U.S. shell bank or is providing banking services indirectly to a non-U.S. shell bank; (iv) is a senior non-U.S. political figure or an immediate family member or close associate of such figure; or (v) is
otherwise prohibited from investing in the Company pursuant to applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations, rules or orders (categories (i) through (v), each a “Prohibited
Purchaser”). The Purchaser agrees to provide the Company, promptly upon request, all information that the Company reasonably deems necessary or appropriate to comply with applicable U.S. anti-money laundering, anti-terrorist and asset
control laws, regulations, rules and orders. The Purchaser consents to the disclosure to U.S. regulators and law enforcement authorities by the Company and its Affiliates and agents of such information about the Purchaser as the Company reasonably
deems necessary or appropriate to comply with applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations, rules and orders. If the Purchaser is a financial institution that is subject to the USA Patriot Act, the
Purchaser represents that it has met all of its obligations under the USA Patriot Act. The Purchaser acknowledges that if, following its investment in the Company, the Company reasonably believes that the Purchaser is a Prohibited Purchaser

  
 15 

	 	
or is otherwise engaged in suspicious activity or refuses to promptly provide information that the Company requests, the Company has the right or may be obligated to prohibit additional
investments, segregate the assets constituting the investment in accordance with applicable regulations or immediately require the Purchaser to transfer the Shares. The Purchaser further acknowledges that the Purchaser will have no claim
against the Company or any of its Affiliates or agents for any form of damages as a result of any of the foregoing actions. 

If the Purchaser is an Affiliate of a non-U.S. banking institution (a “Foreign Bank”), or if the Purchaser receives
deposits from, makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, the Purchaser represents and warrants to the Company that: (i) the Foreign Bank has a fixed address, other than solely an electronic
address, in a country in which the Foreign Bank is authorized to conduct banking activities; (ii) the Foreign Bank maintains operating records related to its banking activities; (iii) the Foreign Bank is subject to inspection by the banking
authority that licensed the Foreign Bank to conduct banking activities; and (iv) the Foreign Bank does not provide banking services to any other Foreign Bank that does not have a physical presence in any country and that is not a regulated
Affiliate. 
  

	 	k.	The Purchaser or its duly authorized representative realizes that because of the inherently speculative nature of businesses of the kind conducted and contemplated by the Company, the Company’s financial results
may be expected to fluctuate from month to month and from period to period and will, generally, involve a high degree of financial and market risk that could result in substantial or, at times, even total losses for investors in securities of the
Company. 

  

	 	l.	The Purchaser has adequate means of providing for its current and anticipated financial needs and contingencies, is able to bear the economic risk for an indefinite period of time and has no need for liquidity of the
investment in the Shares and could afford complete loss of such investment. 

  

	 	m.	The Purchaser is not subscribing for Shares as a result of or subsequent to any advertisement, article, notice or other communication, published in any newspaper, magazine or similar media or broadcast over television,
radio, or the internet, or presented at any seminar or meeting, or any solicitation of a subscription by a person not previously known to the Purchaser in connection with investments in securities generally. 

 

	 	n.	The Purchaser acknowledges that no U.S. federal or state agency or any other government or governmental agency has passed upon the Shares or made any finding or determination as to the fairness, suitability or wisdom of
any investments therein. 

  

	 	o.	 Other than consummating the transactions contemplated hereunder, the Purchaser has not directly or indirectly,
nor has any individual or entity acting on behalf of or pursuant to any understanding with such Purchaser, executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such
Purchaser first received a term sheet (written or oral) from the Company or any other individual or entity representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the
execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have
no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the 

  
 16 

	 	
representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this
Agreement. Other than to other individuals or entities party to this Agreement, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this
transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of,
available shares to borrow in order to effect Short Sales or similar transactions in the future. For purposes of this Agreement, “Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under
the Exchange Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock). 

  

	 	p.	The Purchaser agrees to be bound by all of the terms and conditions of the Registration Rights Agreement and to perform all obligations thereby imposed upon it. 

 

	 	q.	The Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of the Shares and other activities with respect to the Shares by the Purchasers. 

 

	 	r.	All of the information that the Purchaser has heretofore furnished or which is set forth herein is true, correct and complete as of the date of this Agreement, and, if there should be any material change in such
information prior to the admission of the undersigned to the Company, the Purchaser will promptly furnish revised or corrected information to the Company. 

  

	 	s.	(For ERISA plans only) The fiduciary of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), plan (the “Plan”) represents that such
fiduciary has been informed of and understands the Company’s investment objectives, policies and strategies, and that the decision to invest “plan assets” (as such term is defined in ERISA) in the Company is consistent with the
provisions of ERISA that require diversification of plan assets and impose other fiduciary responsibilities. The Purchaser fiduciary or Plan (a) is responsible for the decision to invest in the Company; (b) is independent of the Company or any of
its Affiliates; (c) is qualified to make such investment decision; and (d) in making such decision, the Purchaser fiduciary or Plan has not relied primarily on any advice or recommendation of the Company or any of its Affiliates. 

 

	 	6.	Transfer Restrictions. The Purchaser acknowledges and agrees as follows: 

  

	 	a.	The Shares have not been registered for sale under the Securities Act, in reliance on the private offering exemption in Section 4(a)(2) thereof; other than as expressly provided in the Registration Rights Agreement, the
Company does not currently intend to register the Shares under the Securities Act at any time in the future; and the undersigned will not immediately be entitled to the benefits of Rule 144 with respect to the Shares. 

 

	 	b.	The Purchaser understands that there are substantial restrictions on the transferability of the Shares that the certificates representing the Shares shall bear a restrictive legend in substantially the following
form (and a stop-transfer order may be placed against transfer of such certificates or other instruments): 

 THE SECURITIES
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE 

  
 17 

 
“SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A
REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS.. 

In addition, if any Purchaser is an Affiliate of the Company, certificates evidencing the Shares issued to such Purchaser shall bear a
customary “Affiliates” legend. 
 The legend set forth above shall be removed and the Company shall issue a certificate without
such legend to the holder of the Shares upon which it is stamped, if (a) such Shares are sold pursuant to a registration statement under the Securities Act, or (b) such holder delivers to the Company an opinion of counsel, reasonably
acceptable to the Company, that a disposition of the Shares is being made pursuant to an exemption from such registration and that the Shares, after such transfer, shall no longer be “restricted securities” within the meaning of Rule 144.

  

	 	c.	 Subject to the Company’s right to request an opinion of counsel as set forth in Section 6b,
the legend set forth in Section 6b above shall be removable and the Company shall issue or cause to be issued a book entry position or a certificate without such legend or any other legend to the holder of the applicable Shares upon
which it is stamped or issue or cause to be issued to such holder by electronic delivery at the applicable balance account at The Depository Trust Company (“DTC”) as provided in this Section 6c, if (i) such
Shares and Underlying Shares are registered for resale under the Securities Act and the Purchaser is selling pursuant to the effective registration statement the Shares for resale (the Purchaser hereby agrees to only sell such Shares during such
time that such registration statement is effective and not withdrawn or suspended, and only as permitted by such registration statement), (ii) such Shares are sold or transferred in compliance with Rule 144 (if the transferor is not an Affiliate of
the Company), or (iii) such Shares are eligible for sale without the requirement for the Company to be in compliance with the current public information requirements of Rule 144 as to such securities and without volume or manner-of-sale restrictions
if applicable to the Company at the time of such sale or transfer, and the holder and its broker have delivered customary documents reasonably requested by the Company’s transfer agent and/or Company counsel in connection with such sale or
transfer. All costs and expenses related to the removal of the legends and the reissuance of any Shares or Underlying Shares, including but not limited to costs and expenses with respect to the transfer agent, Company counsel or otherwise, shall be
borne by the Company. Following the date on which the Registration Statement (as defined in the Registration Rights Agreement) is first declared effective by the SEC, or at such other time as a legend is no longer required for certain Shares, the
Company will no later than three (3) Trading Days (as defined below) following the delivery by a Purchaser to the Company or the transfer agent (with concurrent notice and delivery of copies to the Company) of a legended certificate representing
such Shares (endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer, and together with such other customary documents as the transfer agent and/or Company counsel shall
reasonably request), deliver or cause to be delivered to the transferee 

  
 18 

	 	
of such Purchaser or such Purchaser, as applicable, a book entry position or a certificate representing such Shares that is free from all restrictive and other legends. The Company may not make
any notation on its records or give instructions to the transfer agent that enlarge the restrictions on transfer set forth in this Section 6. Certificates for Shares subject to legend removal hereunder shall be transmitted by the
transfer agent to the Purchasers, as applicable, by crediting the account of the transferee’s Purchaser’s prime broker with DTC. “Trading Day” means (i) a day on which the Common Stock is listed or quoted and traded
on its principal trading market (unless the principal trading market is the OTC Bulletin Board or the OTC Pink tier of the OTC Markets Group, Inc.), or (ii) if the Common Stock is not listed on a trading market (other than the OTC Bulletin Board or
the OTC QB, OTC QX or OTC Pink tier of the OTC Markets Group, Inc.), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock is not quoted on any trading market
(other than the OTC QB, OTC QX or OTC Pink tier of the OTC Markets Group, Inc.), a day on which the Common Stock is quoted in the over-the-counter market as reported by the OTC QB, OTC QX or OTC Pink tier of the OTC Markets Group, Inc. (or any
similar organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i), (ii) and (iii) hereof, then Trading Day shall mean a Business Day.

  

	 	d.	If the Company shall fail for any reason or for no reason to issue to a Purchaser a book-entry position or a certificate not bearing the legend set forth in Section 6b within three (3) Trading Days after
receipt by the Company and the Transfer Agent of all documents necessary for the removal of the legend as set forth in Section 6c at a time at which such removal is not prohibited under applicable law (the “Deadline
Date”) (such certificate, the “Unlegended Certificate”), then, in addition to all other remedies available to such Purchaser, if on or after the Trading Day immediately following such three (3) Trading Day
period, such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of the shares of Common Stock to be represented by the Unlegended Certificate that such
Purchaser anticipated receiving from the Company without any restrictive legend as a result of such Purchaser’s full compliance with Section 6c (a “Buy-In”), then the Company shall, within three (3) Trading
Days after such Purchaser’s request and in such Purchaser’s sole discretion, either (i) pay cash to the Purchaser in an amount equal to such Purchaser’s total purchase price (including brokerage commissions, if any) for the shares of
Common Stock so purchased (the “Buy-In Price”), at which point the Company’s obligation to deliver such Unlegended Certificate representing such number of shares of Common Stock so purchased (and to issue such shares of
Common Stock) shall terminate, or (ii) promptly honor its obligation to deliver to such Purchaser a certificate or certificates representing such shares of Common Stock and pay cash to the Purchaser in an amount equal to the excess (if any) of the
Buy-In Price over the product of (a) such number of shares of Common Stock, times (b) the closing price of the Common Stock on the Deadline Date as reported by the principal trading market on which the Common Stock is primarily listed or quoted for
trading. The Purchaser of shares of Common Stock shall provide the Company written notice indicating the amounts payable to such Purchaser in respect of the Buy-In, together with applicable confirmations and other evidence reasonably requested by
the Company. 

  

	 	7.	Conditions to Company’s Obligations at Closing. The Company’s obligation to complete the sale and issuance of the Shares and deliver the Shares to each Purchaser, individually, at each
Closing shall be subject to the following conditions to the extent not waived by the Company: 

  

	 	a.	Receipt of Payment. The Company shall have received payment, by certified or other bank check or by wire transfer of immediately available funds, in the full amount of the purchase price for the number of
Shares being purchased by such Purchaser at such Closing. 

  
 19 

	 	b.	Representations and Warranties. The representations and warranties made by the Purchasers in Section 5 hereof shall be true and correct in all material respects
when made, and shall be true and correct in all material respects on such Closing Date with the same force and effect as if they had been made on and as of said date. The Purchaser shall have performed in all material respects all obligations and
covenants herein required to be performed by them on or prior to such Closing Date. 

  

	 	c.	Receipt of Executed Documents. Such Purchaser shall have executed and delivered to the Company the Omnibus Signature Page, the Purchaser Questionnaire and the Selling Stockholder Questionnaire.

  

	 	d.	Effectiveness of the Merger. The Merger and the related split-off transaction shall have been effected (or is simultaneously effected). 

 

	 	e.	Minimum Offering. The Initial Closing shall be at least for the number of shares of Common Stock in the Minimum Offering at the Purchase Price. 

 

	 	8.	Conditions to Purchasers’ Obligations at Closing. Each Purchaser’s obligation to accept delivery of the Shares and to pay for the Shares shall be subject to the following conditions to the extent not
waived by the Placement Agents on behalf of the Purchasers: 

  

	 	a.	Representations and Warranties Correct. The representations and warranties made by the Company in Section 4 hereof shall be true and correct in all material
respects (except to the extent any such representation and warranty is qualified by materiality or reference to Material Adverse Effect, in which case, such representation and warranty shall be true and correct in all respects as so qualified) as
of, and as if made on, the date of this Agreement and as of such Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct
as of such earlier date. The Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to such Closing Date. 

 

	 	b.	Receipt of Executed Transaction Documents. The Company shall have executed and delivered to the Placement Agents the Registration Rights Agreement and the Escrow Agreement. 

 

	 	c.	Effectiveness of the Merger. The Merger and the related split-off transaction shall have been effected (or is simultaneously effected). 

 

	 	d.	Minimum Offering. The Initial Closing shall be at least for the number of shares of Common Stock in the Minimum Offering at the Purchase Price. 

 

	 	e.	Legal Opinion. Morgan, Lewis & Bockius LLP, counsel to the Company, shall deliver to the Placement Agents an opinion addressed to the Purchasers, dated as of such Closing Date, in form and substance
reasonably acceptable to the Purchasers. 

  
 20 

	 	f.	Certificate. The Chief Executive Officer of the Company shall execute and deliver to the Placement Agents a certificate addressed to the Purchasers to the effect that the representations and warranties of
the Company in Section 4 hereof are true and correct (except to the extent any such representation and warranty is qualified by materiality or reference to Material Adverse Effect, in which case, such
representation and warranty shall be true and correct in all respects as so qualified) as of, and as if made on, the date of this Agreement and as of such Closing Date and that the Company has satisfied in all material respects all of the conditions
set forth in this Section 8. 

  

	 	g.	Good Standing. The Company and each of its subsidiaries is a corporation or other business entity duly organized, validly existing, and in good standing under the laws of the jurisdiction of its formation.

  

	 	h.	OTC Markets Approval. The Company shall be quoted on either the OTC QX or OTC QB. 

  

	 	i.	Judgments. No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any governmental
authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby. 

 

	 	j.	No Suspension. No suspension of trading shall have been imposed by the OTC QB, the SEC or any other governmental regulatory body with respect to public trading in the Common Stock. 

 

	 	k.	Lock-up Agreements. Each of the lock-up agreements, duly executed by the persons listed on Exhibit B hereto, in the form attached as Exhibit C hereto shall have
been delivered to the Placement Agents on behalf of the Purchasers. 

  

	 	l.	Delivery of Draft of Super 8-K. A substantially complete draft of the Super 8-K, including audited financial statements of Valeritas for the years ended December 31, 2014 and 2015 and interim unaudited
financial statements and pro forma financial statements have been delivered to the Placement Agents on behalf of the Purchasers. 

  

	 	m.	Debt Restructuring. Valeritas’s debt conversion and restructuring described as described in Schedule 4c shall have been completed. 

 

	 	9.	Indemnification. 

  

	 	a.	 The Company agrees to indemnify and hold harmless the Purchaser, and its directors, officers, shareholders,
members, partners, employees and agents (and any other persons with a functionally equivalent role of a person holding such titles notwithstanding a lack of such title or any other title), each person who controls such Purchaser (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other persons with a functionally equivalent role of a person holding such
titles notwithstanding a lack of such title or any other title) of such controlling person, from and against all losses, liabilities, claims, damages, costs, fees and expenses whatsoever (including, but not limited to, any and all expenses incurred
in investigating, preparing or defending against any litigation commenced or threatened) based upon or arising out of the Company’s actual or alleged false 

  
 21 

	 	
acknowledgment, representation or warranty, or misrepresentation or omission to state a material fact, or breach by the Company of any covenant or agreement made by the Company, contained herein
or in any other any other Disclosure Materials; provided, however, that the Company will not be liable in any such case to the extent and only to the extent that any such loss, liability, claim, damage, cost, fee or expense arises out of or is based
upon the inaccuracy of any representations made by such indemnified party in this Agreement, or the failure of such indemnified party to comply with the covenants and agreements contained in Section 7. The liability of the Company under this
paragraph shall not exceed the total Purchase Price paid by the Purchaser hereunder, except in the case of fraud. 

  

	 	b.	Promptly after receipt by an indemnified party under this Section 9 of notice of the commencement of any Action, such indemnified party will, if a claim in respect thereof is to be made against the
indemnifying party under this Section 9, notify the indemnifying party in writing of the commencement thereof; but the omission so to notify the indemnifying party will not relieve it from any liability which it may have to any
indemnified party otherwise than under this Section 9. In case any such Action is brought against any indemnified party, and it notifies the indemnifying party of the commencement thereof, the indemnifying party will be entitled
to participate therein, and to the extent that it may elect by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof, with counsel satisfactory to
such indemnified party; provided, however, if the defendants in any such Action include both the indemnified party and the indemnifying party and either (i) the indemnifying party or parties and the indemnified party or parties mutually agree or
(ii) representation of both the indemnifying party or parties and the indemnified party or parties by the same counsel is inappropriate under applicable standards of professional conduct due to actual or potential differing interests between them,
the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such Action on behalf of such indemnified party or parties. Upon receipt of notice
from the indemnifying party to such indemnified party of its election so to assume the defense of such Action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this
Section 9 for any reasonable legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed counsel in connection with the assumption
of legal defenses in accordance with the proviso to the next preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the expenses of more than one separate counsel in such circumstance), (ii) the
indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the Action or (iii) the indemnifying party has authorized the
employment of counsel for the indemnified party at the expense of the indemnifying party. No indemnifying party shall (i) without the prior written consent of the indemnified parties (which consent shall not be unreasonably withheld), settle or
compromise or consent to the entry of any judgment with respect to any pending or threatened Action in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified parties are actual or potential parties
to such Action) unless such settlement, compromise or consent includes an unconditional release of each indemnified party from all liability arising out of such Action, or (ii) be liable for any settlement of any such Action effected without its
written consent (which consent shall not be unreasonably withheld), but if settled with its written consent or if there be a final judgment of the plaintiff in any such Action, the indemnifying party agrees to indemnify and hold harmless any
indemnified party from and against any loss or liability by reason of such settlement or judgment. 

  
 22 

	 	10.	Revocability; Binding Effect. The subscription hereunder may be revoked prior to the Closing thereon, provided that written notice of revocation is sent and is received by the Company or a Placement Agent at
least three (3) Business Days prior to the Closing on such subscription. The Purchaser hereby acknowledges and agrees that this Agreement shall survive the death or disability of the Purchaser and shall be binding upon and inure to the benefit of
the parties and their heirs, executors, administrators, successors, legal representatives and permitted assigns. If the Purchaser is more than one person, the obligations of the Purchaser hereunder shall be joint and several and the agreements,
representations, warranties and acknowledgments herein shall be deemed to be made by and be binding upon each such person and such person’s heirs, executors, administrators, successors, legal representatives and permitted assigns.

  

	 	11.	Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under this Agreement are several and not joint with the obligations of any other Purchaser, and no Purchaser shall
be responsible in any way for the performance of the obligations of any other Purchaser under this Agreement. Nothing contained herein and no action taken by any Purchaser pursuant hereto, shall be deemed to constitute the Purchasers as a
partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group, or are deemed affiliates (as such term is defined under the Exchange Act) with
respect to such obligations or the transactions contemplated by this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not
be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. 

  

	 	12.	Third-Party Beneficiary. The Placement Agents shall be the third party beneficiary of the representations and warranties included in this Agreement. This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 9 and this Section
12. 

  

	 	13.	Modification. This Agreement shall not be modified or waived except by an instrument in writing signed by the party against whom any such modification or waiver is sought to be enforced. 

 

	 	14.	Immaterial Modifications to the Registration Rights Agreement. The Company and the Placement Agents may, at any time prior to the initial Closing, amend the Registration Rights Agreement if necessary to
clarify any provision therein, without first providing notice or obtaining prior consent of the Purchaser. 

  
 23 

	 	15.	Notices. Any notice, consents, waivers or other communication required or permitted to be given hereunder shall be in writing and will be deemed to have been delivered: (i) upon receipt, when personally
delivered; (ii) upon receipt when sent by certified mail, return receipt requested, postage prepaid; (iii) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by
the sending party); (iv) when sent, if by e-mail, (provided that such sent e-mail is kept on file (whether electronically or otherwise) by the sending party and the sending party does not receive an automatically generated message from the
recipient’s e-mail server that such e-mail could not be delivered to such recipient); or (v) one (1) Business Day after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed to the party to
receive the same. The addresses, facsimile numbers and email addresses for such communications shall be: 

  

	 	(a)	if to the Company, at 

 Valeritas Holdings, Inc. 

750 Route 202 South, Suite 600 

Bridgewater, NJ 08807 

Attention: Chief Executive Officer 

Facsimile: 908-927-9927 

E-mail: JTimberlake@valeritas.com 

with copies (which shall not constitute notice) to: 

CKR Law LLP 
 1330 Avenue of the
Americas 
 New York, NY 10019 

Attention: Barrett S. DiPaolo 

Facsimile: +1-212-259-8200 

E-mail: bdipaolo@ckrlaw.com 

and 
 Morgan, Lewis &
Bockius LLP 
 502 Carnegie Center 

Princeton, NJ 08540-6241 

Attention: Emilio Ragosa 

Facsimile: 609-919-6701 

Email: eragosa@morganlewis.com, 

or 
  

	 	(b)	if to the Purchaser, at the address set forth on the Omnibus Signature Page hereof. 

 (or, in
either case, to such other address as the party shall have furnished in writing in accordance with the provisions of this Section 15). Any notice or other communication given by certified mail shall be deemed given at the time of
certification thereof, except for a notice changing a party’s address which shall be deemed given at the time of receipt thereof. 
  

	 	16.	Assignability. This Agreement and the rights, interests and obligations hereunder are not transferable or assignable by the Purchaser, and the transfer or assignment of the Shares shall be made only in
accordance with all applicable laws. 

  

	 	17.	Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without reference to the principles thereof relating to the conflict of laws.

  

	 	18.	Arbitration. The parties agree to submit all controversies to arbitration in accordance with the provisions set forth below and understand that: 

 

	 	a.	Arbitration shall be final and binding on the parties. 

  
 24 

	 	b.	The parties are waiving their right to seek remedies in court, including the right to a jury trial. 

  

	 	c.	Pre-arbitration discovery is generally more limited and different from court proceedings. 

  

	 	d.	The arbitrator’s award is not required to include factual findings or legal reasoning and any party’s right to appeal or to seek modification of rulings by arbitrators is strictly limited. 

 

	 	e.	The panel of arbitrators will typically include a minority of arbitrators who were or are affiliated with the securities industry. 

  

	 	f.	All controversies which may arise between the parties concerning this Agreement shall be determined by arbitration pursuant to the rules then pertaining to the Financial Industry Regulatory Authority in New York City,
New York. Judgment on any award of any such arbitration may be entered in the Supreme Court of the State of New York or in any other court having jurisdiction of the person or persons against whom such award is rendered. Any notice of such
arbitration or for the confirmation of any award in any arbitration shall be sufficient if given in accordance with the provisions of this Agreement. The parties agree that the determination of the arbitrators shall be binding and conclusive
upon them. The prevailing party, as determined by such arbitrators, in a legal proceeding shall be entitled to collect any costs, disbursements and reasonable attorney’s fees from the other party. Prior to filing an arbitration, the parties
hereby agree that they will attempt to resolve their differences first by submitting the matter for resolution to a mediator, acceptable to all parties, and whose expenses will be borne equally by all parties. The mediation will be held in the
County of New York, State of New York, on an expedited basis. If the parties cannot successfully resolve their differences through mediation within sixty (60) days from the receipt of the written notice of a matter from the notifying party, the
matter will be resolved by arbitration. The arbitration shall take place in the County of New York, State of New York, on an expedited basis. 

  

	 	19.	Form D; Blue Sky Qualification. The Company agrees to timely file a Form D with respect to the Securities and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action
as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchaser at such Closing under applicable securities or “Blue Sky” laws of the states of the United
States, and shall provide evidence of such actions promptly upon request of any Purchaser. 

  

	 	20.	Use of Pronouns. All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the person or persons referred to may
require. 

  

	 	21.	 Securities Laws Disclosure; Publicity. By 9:00 a.m., New York City time, on the trading day
immediately following the execution of this Agreement, the Company shall issue a press release (the “Press Release”) disclosing all material terms of the Offering. Within the time required by the Exchange Act, the Company
will file the Super 8-K (and including as exhibits to such Super 8-K, the material Transaction Documents (including, without limitation, this Agreement and the Registration Rights Agreement)). Notwithstanding the foregoing, the Company shall not
publicly disclose the name of any Purchaser or an Affiliate of any Purchaser, or include the name of any Purchaser or an Affiliate of any Purchaser in any press release or filing with the SEC (other than the Registration Statement) or any regulatory
agency or principal trading market, without the prior written consent of such Purchaser, except (i) as required by federal securities law in 

  
 25 

	 	
connection with (A) any registration statement contemplated by the Registration Rights Agreement and (B) the filing of final Transaction Documents with the SEC or (ii) to the
extent such disclosure is required by law, request of the staff of the SEC or of any regulatory agency or principal trading market regulations, in which case the Company shall provide the Purchasers with prior written notice of such disclosure
permitted under this sub-clause (ii) from and after the issuance of the Press Release, no Purchaser shall be in possession of any material, non-public information received from the Company or any of its respective officers, directors, employees or
agents, that is not disclosed in the Press Release unless a Purchaser shall have executed a written agreement regarding the confidentiality and use of such information. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company as described in this Section 21, such Purchaser will maintain the confidentiality of all
disclosures made to it in connection with such transactions (including the existence and terms of such transactions). 

  

	 	22.	Non-Public Information. Except for information (including the terms of this Agreement and the transactions contemplated hereby) that will be disclosed in the Super 8-K and filed with the SEC within four (4)
Business Days of the Initial Closing, the Company shall not and shall cause each of its officers, directors, employees and agents, not to, provide any Purchaser with any material, non-public information regarding the Company without the express
written consent of such Purchaser. 

  

	 	23.	Anti-Dilution. If within six (6) months after the Initial Closing of the Offering the Company shall issue Additional Shares of Common Stock (as defined below) for a consideration per share, or with an
exercise or conversion price per share, less than the Purchase Price (adjusted proportionately (or if it cannot be adjusted proportionately, then equitably) for any event described in clause (iii) of the following paragraph occurring after the first
Closing of the Offering) (the “Lower Price”), the Purchaser shall be entitled to receive from the Company (for no additional consideration) additional Shares in an amount such that, when added to the number of shares of
Common Stock initially purchased by the Purchaser in the Offering and still held by such Purchaser at the time of the dilutive issuance (the “Held Shares”), will equal the number of shares of Common Stock that such
Purchaser’s aggregate Purchase Price for the Held Shares would have purchased at the Lower Price. Holders of a majority of the then Held Shares may waive the anti-dilution rights of all Purchasers with respect to a particular issuance by the
Company. 

 “Additional Shares of Common Stock” shall mean all shares of Common Stock issued by the
Company after the Initial Closing of the Offering (including without limitation any shares of Common Stock issuable upon conversion or exchange of any convertible securities or upon exercise of any option, warrant or other right, on an as-converted
or as-exercised basis, as of the date of issuance of such security, option, warrant or right), other than: (i) shares of Common Stock issued or issuable upon conversion or exchange of any convertible securities or exercise of any options or warrants
outstanding as of immediately following the Merger and the initial Closing; (ii) shares of Common Stock issued or issuable upon exercise of the Placement Agent Warrants; (iii) shares of Common Stock issued in a Subsequent Closing; (iv) shares
of Common Stock issued or issuable by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock relating to any recapitalization, reclassification or reorganization of the capital stock of the Company or otherwise,
or any consolidation or merger of the Company with another corporation, or the sale of all or substantially all of its assets or other transaction effected in such a way that there is no change of control of the Company; (v) shares of Common Stock
issued or issuable pursuant to the acquisition of another entity or business by the Company by merger, purchase of substantially all of the assets or other reorganization or pursuant to a joint 

  
 26 

 
venture or technology license agreement, but not including a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary
business is investing in securities; (vi) shares of Common Stock issued or issuable to officers, directors and employees of, or consultants to, the Company pursuant to stock grants, option plans, purchase plans or other employee stock incentive
programs or arrangements approved by the Board of Directors, or upon exercise of options or warrants granted to such parties pursuant to any such plan or arrangement; and (vii) securities issued to financial institutions, institutional investors or
lessors in connection with credit arrangements, equipment financings, lease arrangements or similar transactions, in the aggregate not exceeding ten percent (10%) of the number of shares of Common Stock outstanding at any time, and in case of
clauses (iv) through (vii) above, such issuance is approved by a majority of disinterested directors of the Company and includes no “death spiral” provision of any kind. 

 

	 	24.	Miscellaneous. 

  

	 	a.	This Agreement, together with the Registration Rights Agreement and any confidentiality agreement between the Purchaser and the Company, constitute the entire agreement between the Purchaser and the Company with respect
to the Offering and supersede all prior oral or written agreements and understandings, if any, relating to the subject matter hereof. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only
by a written document executed by the party entitled to the benefits of such terms or provisions. 

  

	 	b.	The representations and warranties of the Company and the Purchaser made in this Agreement shall survive the execution and delivery hereof and delivery of the Shares. 

 

	 	c.	If the Shares are certificated and any certificate or instrument evidencing any Shares or Placement Agent Warrants is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and
substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company and the Company’s transfer agent of such loss,
theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless the Company and the Company’s transfer agent for any losses in connection
therewith or, if required by the transfer agent, a bond in such form and amount as is required by the transfer agent. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs
associated with the issuance of such replacement Shares or Placement Agent Warrants. If a replacement certificate or instrument evidencing any Shares or Placement Agent Warrants is requested due to a mutilation thereof, the Company may require
delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement. 

  

	 	d.	Each of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others engaged by such party) in connection with this Agreement and the transactions
contemplated hereby, whether or not the transactions contemplated hereby are consummated. 

  

	 	e.	 This Agreement may be executed in one or more original or facsimile or by an e-mail which contains a portable
document format (.pdf) file of an executed signature page counterparts, each of which shall be deemed an original, but all of which shall together constitute one and the same instrument and which shall be enforceable against the parties actually
executing 

  
 27 

	 	
such counterparts. The exchange of copies of this Agreement and of signature pages by facsimile transmission or in .pdf format shall constitute effective execution and delivery of this Agreement
as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile or by e-mail of a document in pdf format shall be deemed to be their original signatures for all purposes.

  

	 	f.	Each provision of this Agreement shall be considered separable and, if for any reason any provision or provisions hereof are determined to be invalid or contrary to applicable law, such invalidity or illegality shall
not impair the operation of or affect the remaining portions of this Agreement. 

  

	 	g.	Paragraph titles are for descriptive purposes only and shall not control or alter the meaning of this Agreement as set forth in the text. 

 

	 	h.	The Purchaser understands and acknowledges that there may be multiple Closings for the Offering. 

  

	 	i.	The Purchaser hereby agrees to furnish the Company such other information as the Company may request prior to the Closing with respect to its subscription hereunder. 

 

	 	25.	Omnibus Signature Page. This Agreement is intended to be read and construed in conjunction with the Registration Rights Agreement. Accordingly, pursuant to the terms and conditions of this Agreement and
the Registration Rights Agreement, it is hereby agreed that the execution by the Purchaser of this Agreement, in the place set forth on the Omnibus Signature Page below, shall constitute agreement to be bound by the terms and conditions hereof and
the terms and conditions of the Registration Rights Agreement, with the same effect as if each of such separate but related agreement were separately signed. 

  

	 	26.	Public Disclosure. Neither the Purchaser nor any officer, manager, director, member, partner, stockholder, employee, Affiliate, affiliated person or entity of the Purchaser shall make or issue any press releases
or otherwise make any public statements or make any disclosures to any third person or entity with respect to the transactions contemplated herein and will not make or issue any press releases or otherwise make any public statements of any nature
whatsoever with respect to the Company without the Company’s express prior approval. The Company has the right to withhold such approval in its sole discretion. 

 

	 	27.	Potential Conflicts. The Placement Agents, their sub-agents, legal counsel to the Company or Valeritas and/or their respective Affiliates, principals, representatives or employees may now or hereafter
own shares of the Company. 

 [Signature page follows.] 

  
 28 

 IN WITNESS WHEREOF, the Company has duly executed this Agreement as of the      day of
            , 2016. 
  

					
	VALERITAS HOLDINGS, INC.
		
	By:	 	  

		 	Name:	 	John Timberlake
		 	Title:	 	Chief Executive Officer

  
 29 

 Annex A 

How to subscribe for Shares in the private offering of 

Valeritas Holdings, Inc. 

(f/k/a Cleaner Yoga Mat, Inc.): 
  

	1.	Date and Fill in the number of Shares being purchased and complete and sign the Omnibus Signature Page. 

  

	2.	Initial the Accredited Investor Certification in the appropriate place or places. 

  

	3.	Complete and sign the Investor Profile. 

  

	4.	Complete and sign the Anti-Money Laundering Information Form. 

  

	5.	Fax or email all forms and then send all signed original documents to: 

 CKR LAW
LLP 
 1330 Avenue of the Americas 

New York, NY 10019 

Facsimile Number: (212) 259-8200 

Telephone Number: (212) 259-7300 

Attn: Kathleen L. Rush 

E-mail Address: krush@CKRlaw.com 
  

	6.	If you are paying the Purchase Price by check, a certified or other bank check for the exact dollar amount of the Purchase Price for the number of Shares you are purchasing should be made payable to
the order of “Delaware Trust Company, as Escrow Agent for Valeritas Holdings, Inc., Acct. # 79-2652” and should be sent directly to Delaware Trust Company, 2711 Centerville Road, One Little Falls Centre, Wilmington,
DE 19808, Attn: Alan R. Halpern. 

 Checks take up to five (5) business days to
clear. A check must be received by the Escrow Agent at least six (6) business days before the closing date. 
  

	7.	If you are paying the Purchase Price by wire transfer, you should send a wire transfer for the exact dollar amount of the Purchase Price for the number of Shares you are purchasing according to the
following instructions: 

  

			
	Bank:	  	 PNC Bank
 300 Delaware Avenue

Wilmington, DE 19899

	ABA Routing #:	  	031100089
	SWIFT CODE:	  	PNCCUS33
	Account Name:	  	Delaware Trust Company
	Account #:	  	5605012373
	Reference:	  	 “FFC: Valeritas Holdings, Inc. Escrow Acct. #

79-2652 – [INSERT SUBSCRIBER’S NAME]”

	Delaware Trust Contact:	  	Alan R. Halpern

 Thank you for your interest, 

Valeritas Holdings, Inc. 

 Valeritas Holdings, Inc. (f/k/a Cleaner Yoga Mat, Inc.) 

OMNIBUS SIGNATURE PAGE TO 

SUBSCRIPTION AGREEMENT AND REGISTRATION RIGHTS AGREEMENT 

The undersigned, desiring to: (i) enter into the Subscription Agreement, dated as of             
    ,1 2016 (the “Subscription Agreement”), between the undersigned, Valeritas Holdings, Inc. (f/k/a Cleaner Yoga Mat, Inc.), a Delaware corporation (the
“Company”), and the other parties thereto, in or substantially in the form furnished to the undersigned, (ii) enter into the Registration Rights Agreement (the “Registration Rights Agreement”), among the undersigned, the Company
and the other parties thereto, in or substantially in the form furnished to the undersigned, and (iii) purchase the Shares of the Company’s securities as set forth in the Subscription Agreement and below, hereby agrees to purchase such Shares
from the Company and further agrees to join the Subscription Agreement and the Registration Rights Agreement as a party thereto, with all the rights and privileges appertaining thereto, and to be bound in all respects by the terms and conditions
thereof. The undersigned specifically acknowledges having read the representations section in the Subscription Agreement entitled “Representations and Warranties of the Purchaser” and hereby represents that the statements contained therein
are complete and accurate with respect to the undersigned as a Purchaser. 
 IN WITNESS WHEREOF, the Purchaser hereby executes this Agreement and the
Registration Rights Agreement. 
 Dated:              , 2016 

 

													
	  
	  	X	  	 $5.00
	  		  	=	  	$	 	  

	Number of Shares	  		  	Purchase Price per Share	  		  	Total Purchase Price

  

							
	SUBSCRIBER (individual)	 		  	SUBSCRIBER (entity)
			
	  
 Signature
	 		  	  
 Name of
Entity

			
	  
 Print Name
	 		  	  
 Signature

				
		 		  	Print Name:	  	  

	  
 Signature (if Joint Tenants or
Tenants in Common)
	 		  	Title:	  	  

			
	Address of Principal Residence:	 		  	Address of Executive Offices:
			
	  
	 		  	  

	  
	 		  	  

	  
	 		  	  

			
	Social Security Number(s):	 		  	IRS Tax Identification Number:
			
	  
	 		  	  

			
	Telephone Number:	 		  	Telephone Number:
			
	  
	 		  	  

			
	Facsimile Number:	 		  	Facsimile Number:
			
	  
	 		  	  

			
	E-mail Address:	 		  	E-mail Address:
			
	  
	 		  	  

  

	1	Will reflect the Closing Date. Not to be completed by Purchaser. 

 Valeritas Holdings, Inc. (f/k/a Cleaner Yoga Mat, Inc.) 

ACCREDITED INVESTOR CERTIFICATION 

For Individual Investors Only 

(all Individual Investors must INITIAL where appropriate): 

 

			
	Initial     	  	I have a net worth of at least US$1 million either individually or through aggregating my individual holdings and those in which I have a joint, community property or other similar shared ownership interest with my spouse.
(For purposes of calculating your net worth under this paragraph, (a) your primary residence shall not be included as an asset; (b) indebtedness secured by your primary residence, up to the estimated fair
market value of your primary residence at the time of your purchase of the securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of your purchase of the securities exceeds the amount
outstanding sixty (60) days before such time, other than as a result of the acquisition of your primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by your primary residence in excess
of the estimated fair market value of your primary residence at the time of your purchase of the securities shall be included as a liability.)
		
	Initial     	  	I have had an annual gross income for the past two (2) years of at least US$200,000 (or US$300,000 jointly with my spouse) and expect my income (or joint income, as appropriate) to reach the same level in the current year.
		
	Initial     	  	I am a director or executive officer of Valeritas Holdings, Inc.
		
		  	 For Non-Individual Investors (Entities)

(all Non-Individual Investors must INITIAL where appropriate):

		
	 Initial     
	  	The investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons who meet at least one of the criteria for Individual Investors set forth above (in which case
each such person must complete the Accreditor Investor Certification for Individuals above as well the remainder of this questionnaire).
		
	 Initial     
	  	The investor certifies that it is a partnership, corporation, limited liability company or business trust that has total assets of at least US$5 million and was not formed for the purpose of investing the Company.
		
	 Initial     
	  	The investor certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in ERISA §3(21)) that is a bank, savings and loan association, insurance company or registered
investment advisor.
		
	 Initial     
	  	The investor certifies that it is an employee benefit plan whose total assets exceed US$5,000,000 as of the date of this Agreement.
		
	Initial     	  	The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who meet at least one of the criteria for Individual Investors.
		
	Initial     	  	The investor certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its individual or fiduciary capacity.
		
	Initial     	  	The undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934.
		
	Initial     	  	The investor certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets exceeding US$5,000,000 and not formed for the specific purpose of investing in the Company.
		
	Initial     	  	The investor certifies that it is a trust with total assets of at least US$5,000,000, not formed for the specific purpose of investing in the Company, and whose purchase is directed by a person with such knowledge and experience in
financial and business matters that such person is capable of evaluating the merits and risks of the prospective investment.
		
	Initial     	  	The investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of
US$5,000,000.
		
	Initial     	  	The investor certifies that it is an insurance company as defined in §2(13) of the Securities Act of 1933, or a registered investment company.

 Valeritas Holdings, Inc. (f/k/a Cleaner Yoga Mat, Inc.) 

Investor Profile 

(Must be completed by Investor) 

Section A - Personal Investor Information 

 

			
	Investor Name(s):	 	  

			
		
	Individual executing Profile or Trustee:	 	  

			
		
	Social Security Numbers / Federal I.D. Number:	 	  

							
				
	Date of Birth:	  	  
	    	Marital Status:	  	  

	Joint Party Date of Birth:	  	  
	    	Investment Experience (Years):	  	  

	Annual Income:	  	  
	    	Liquid Net Worth:	  	  

				
	Net Worth*:	  	  
	    		  	

							
				
	Tax Bracket:	  	         15% or below	  	         25% - 27.5%	  	         Over 27.5%

					
		
	Home Street Address:	 	  

					
		
	Home City, State & Zip Code:	  	  

											
						
	Home Phone:	 	  
	  	Home Fax:	  	  
	  	Home Email:	  	  

					
		
	Employer:	 	  

									
				
	Employer Street Address:	 		 		 	  

									
				
	Employer City, State & Zip Code:	 		 		 	  

											
						
	Bus. Phone:	 	  
	 	Bus. Fax:	 	  
	  	Bus. Email:	  	  

					
		
	Type of Business:	 	  

					
		
	Outside Broker/Dealer:	 	  

 Section B – Certificate Delivery Instructions 

 

	
	         Please deliver certificate to the Employer Address listed in Section A.
	         Please deliver certificate to the Home Address listed in Section A.
	         Please deliver certificate to the following address:
                                        

 Section C – Form of Payment – Check or Wire Transfer 

 

	
	         Check payable to Delaware Trust Company, as Escrow Agent for Valeritas Holdings, Inc., ACCT# 79-2652
	         Wire funds from my outside account according to Section 2(b) of the Subscription Agreement.
	         The funds for this investment are rolled over, tax deferred from
                     within the allowed sixty (60) day window.

 Please check if you are a FINRA member or Affiliate of a FINRA member firm:
                     
  

					
	  
	 		 	  

	Investor Signature	 		 	Date

  

	*	For purposes of calculating your net worth in this form, (a) your primary residence shall not be included as an asset; (b) indebtedness secured by your primary residence, up to the estimated fair market value
of your primary residence at the time of your purchase of the securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of your purchase of the securities exceeds the amount outstanding
sixty (60) days before such time, other than as a result of the acquisition of your primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by your primary residence in excess of the
estimated fair market value of your primary residence at the time of your purchase of the securities shall be included as a liability. 

 ANTI MONEY LAUNDERING REQUIREMENTS 

The USA PATRIOT Act 
 The USA PATRIOT Act is designed to
detect, deter, and punish terrorists in the United States and abroad. The Act imposes new anti-money laundering requirements on brokerage firms and financial institutions. Since April 24, 2002 all brokerage firms have been required to have
new, comprehensive anti-money laundering programs. 
 To help you understand these efforts, we want to provide you with some information about money
laundering and our steps to implement the USA PATRIOT Act. 
 What is money laundering? 

Money laundering is the process of disguising illegally obtained money so that the funds appear to come from legitimate sources or activities. Money
laundering occurs in connection with a wide variety of crimes, including illegal arms sales, drug trafficking, robbery, fraud, racketeering, and terrorism. 

How big is the problem and why is it important? 
 The use
of the U.S. financial system by criminals to facilitate terrorism or other crimes could well taint our financial markets. According to the U.S. State Department, one recent estimate puts the amount of worldwide money laundering activity at
$1 trillion a year. 
 What are we required to do to eliminate money laundering? 

Under rules required by the USA PATRIOT Act, our anti-money laundering program must designate a special compliance officer, set up employee training, conduct
independent audits, and establish policies and procedures to detect and report suspicious transaction and ensure compliance with such laws. As part of our required program, we may ask you to provide various identification documents or other
information. Until you provide the information or documents we need, we may not be able to effect any transactions for you. 

 ANTI-MONEY LAUNDERING INFORMATION FORM 

The following is required in accordance with the AML provision of the USA PATRIOT ACT. 

(Please fill out and return with requested documentation.) 
  

					
	INVESTOR NAME:	 	  
	 	
			
	LEGAL ADDRESS:	 	  
	 	
			
		 	  
	 	
			
	 SSN# or TAX ID#

OF INVESTOR:
	 	  
	 	
			
	YEARLY INCOME:	 	  
	 	

							
				
	NET WORTH:	 	  
	 	*	 	

  

	*	For purposes of calculating your net worth in this form, (a) your primary residence shall not be included as an asset; (b) indebtedness secured by your primary residence, up to the estimated fair market value
of your primary residence at the time of your purchase of the securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of your purchase of the securities exceeds the amount outstanding
sixty (60) days before such time, other than as a result of the acquisition of your primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by your primary residence in excess of the
estimated fair market value of your primary residence at the time of your purchase of the securities shall be included as a liability. 

  

					
	INVESTMENT OBJECTIVE(S) (FOR ALL INVESTORS):	 	  
	 	

					
			
	ADDRESS OF BUSINESS OR OF EMPLOYER:	 	  
	 	

					
			
		 	  
	 	

					
			
	FOR INVESTORS WHO ARE INDIVIDUALS: AGE:	 	  
	 	

					
			
	FOR INVESTORS WHO ARE INDIVIDUALS: OCCUPATION:	 	  
	 	

					
			
	FOR INVESTORS WHO ARE ENTITIES: TYPE OF BUSINESS:	 	  
	 	

 IDENTIFICATION & DOCUMENTATION AND SOURCE OF FUNDS: 

 

	1.	Please submit a copy of non-expired identification for the authorized signatory(ies) on the investment documents, showing name, date of birth, address and signature. The address shown on the identification
document MUST match the Investor’s address shown on the Investor Signature Page. 

  

									
	Current Driver’s License	  	or	  	Valid Passport	  	or	  	Identity Card

 (Circle one or more) 
  

	2.	If the Investor is a corporation, limited liability company, trust or other type of entity, please submit the following requisite documents: (i) Certificate of Incorporation, By-Laws, Certificate of Formation, Operating
Agreement, Trust or other similar documents for the type of entity; and (ii) Corporate Resolution or power of attorney or other similar document granting authority to signatory(ies) and designating that they are permitted to make the proposed
investment. 

  

	3.	Please advise where the funds were derived from to make the proposed investment: 

  

									
	Investments	  	Savings	  	Proceeds of Sale	  	Other	 	  

 (Circle one or more) 
  

			
	Signature:	 	  

			
		
	Print Name:	 	  

			
		
	Title (if applicable):	 	  

			
		
	Date:	 	  

 DISCLOSURE SCHEDULE 

TO THE 
 SUBSCRIPTION
AGREEMENT 
 by and among 

VALERITAS HOLDINGS, INC. 

and 
 THE PURCHASERS
PARTY THERETO 
 This is the Disclosure Schedule (the “Disclosure Schedule”) to the Subscription Agreement (the
“Subscription Agreement”) executed by each purchaser (collectively the “Purchasers”) in connection with the private placement offering by Valeritas Holdings, Inc. (f/k/a Cleaner Yoga Mat, Inc.), a Delaware
corporation (the “Company”), of a minimum of $25,000,000 and a maximum of $40,000,000 of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), plus up to an additional
$10,000,000 of shares of Common Stock to cover over-subscriptions. 
 To the extent that any representation or warranty contained in the
Subscription Agreement is limited or qualified by the materiality of the matters to which the representation or warranty is given, the inclusion of any matter in this Disclosure Schedule does not constitute a determination that such matters are
material. Nothing in this Disclosure Schedule constitutes an admission of any liability or obligation of the Company or the Purchasers to any third party. 

The representations and warranties set forth in the Subscription Agreement shall be modified by the exceptions, limitations, clarifications
and other matters set forth in this Disclosure Schedule. Any fact or matter discussed in one or more of the items in any section of this Disclosure Schedule shall be deemed to be disclosed for purposes of all other representations and
warranties in the Subscription Agreement, whether or not specifically cross-referenced, to the extent the relevance is reasonably apparent from the disclosure. Unless otherwise specified herein, capitalized terms set forth herein shall have the
meanings ascribed to them in the Subscription Agreement. 

 Schedule 4a 

Subsidiaries 
 The Company’s only
subsidiary is Valeritas, Inc., a Delaware corporation. 

 Schedule 4c 

Pro Forma Capitalization1 

For purposes of this Disclosure Schedule, the term “Issuer” shall mean the Company, and the term “Valeritas” shall have the
meaning as provided in the Subscription Agreement. 
  

																									
	 Minimum Offering
	 
	 	  	 	 	  	 	 	  	Actual	 	 	Fully Diluted	 
	 	  	 	 	  	 	 	  	Shares	 	  	%
Ownership	 	 	Shares	 	  	%
Ownership	 
	 Valeritas Stockholders
	  				  				  	 	6,600,000	  	  	 	52.4	% 	 	 	6,600,000	  	  	 	42.1	% 
	 Offering Shares
	  	 	@	  	  	$	5.00	  	  				  				 				  			
	 Existing Valeritas Investors2
	  				  				  	 	4,000,000	  	  	 	31.7	% 	 	 	4,000,000	  	  	 	25.5	% 
	 New Investors
	  				  				  	 	1,000,000	  	  	 	7.9	% 	 	 	1,000,000	  	  	 	6.4	% 
	 Placement Agent Warrants
	  	 	@	  	  	$	5.00	  	  				  				 	 	8,000	  	  	 	0.5	% 
	 Issuer Pre-Merger Stockholders
	  				  				  	 	1,000,000	  	  	 	7.9	% 	 	 	1,000,000	  	  	 	6.4	% 
	 Equity Incentive Plan
	  				  				  				  				 	 	3,000,000	  	  	 	19.1	% 
		  				  				  	  
	  
	 	  	  
	  
	 	 	  
	  
	 	  	  
	  
	 
	 Total
	  				  				  	 	12,600,000	  	  	 	100.0	% 	 	 	15,680,000	  	  	 	100.0	% 
		  				  				  	  
	  
	 	  	  
	  
	 	 	  
	  
	 	  	  
	  
	 
	
	 Maximum Offering plus
Over-Subscription Option
	 
	 	  	 	 	  	 	 	  	Actual	 	 	Fully Diluted	 
	 	  	 	 	  	 	 	  	Shares	 	  	%
Ownership	 	 	Shares	 	  	%
Ownership	 
	 Valeritas Stockholders
	  				  				  	 	6,600,000	  	  	 	37.5	% 	 	 	6,600,000	  	  	 	31.3	% 
	 Offering Shares
	  	 	@	  	  	$	5.00	  	  				  				 				  			
	 Existing Valeritas Investors3
	  				  				  	 	4,000,000	  	  	 	22.7	% 	 	 	4,000,000	  	  	 	19.0	% 
	 New Investors4
	  				  				  	 	6,000,000	  	  	 	34.1	% 	 	 	6,000,000	  	  	 	28.5	% 
	 Placement Agent Warrants
	  	 	@	  	  	$	5.00	  	  				  				 	 	480,000	  	  	 	2.3	% 
	 Issuer Pre-Merger Stockholders
	  				  				  	 	1,000,000	  	  	 	5.7	% 	 	 	1,000,000	  	  	 	4.7	% 
	 Equity Incentive Plan
	  				  				  				  				 	 	3,000,000	  	  	 	14.2	% 
		  				  				  	  
	  
	 	  	  
	  
	 	 	  
	  
	 	  	  
	  
	 
	 Total
	  				  				  	 	17,600,000	  	  	 	100.0	% 	 	 	21,080,000	  	  	 	100.0	% 
		  				  				  	  
	  
	 	  	  
	  
	 	 	  
	  
	 	  	  
	  
	 

  

	1 	Assumes no exercise of the Issuer’s counsel’s option to receive up to 50% of its fees and expenses relating to the transactions in Common Stock. 

	2 	Assumes participation of $20,000,000 from existing Valeritas investors in $30,000,000 Offering with no sales pursuant to Over-Subscription Option and a closing on or before April 29, 2016. 

	3 	Assumes participation of $20,000,000 from existing Valeritas investors. 

	4 	Assumes participation of $30,000,000 from new investors, including the $10,000,000 Over-Subscription Option. 

 Schedule 4c(i) 

Preemptive Rights 
 None. 

 Schedule 4c(ii) 

Options, Warrants, Other Stock Rights 

Certain options and restricted stock to be issued pursuant to the 2016 Incentive Compensation Plan of Valeritas Holdings, Inc. 

 Schedule 4c(iii) 

Indebtedness 
 Immediately prior to the
Closing Date, Valeritas has outstanding a principal amount of $50 million of senior indebtedness held by Capital Royalty Group and certain of its affiliates (collectively, “CRG”) pursuant to an Amended and Restated Term Loan
Agreement by and between Valeritas and CRG dated as of August 5, 2014 by (as amended, restated or supplemented from time to time, the “Term Loan Agreement”), and a principal amount of $5 million of subordinated indebtedness
held by WCAS Capital Partners IV, L.P. (“WCAS”), an affiliate of Welsh, Carson, Anderson & Stowe, pursuant to a Note issued by Valeritas to WCAS, dated September 8, 2011, as amended by Amendment No. 1 to Note dated as of May 24,
2013 (as further amended, restated or supplemented from time to time, the “WCAS Note”). 
 Accrued interest, fees and expenses on the
principal indebtedness held by CRG pursuant to the Term Loan Agreement and by WCAS pursuant to the WCAS Note as of April 29, 2016 will be $16,574,604.12 (the “CRG Interest”) and $2,075,662.72 (the “WCAS Interest”),
respectively, for a total amount of $18,650,266.84. Pursuant to negotiations with CRG and WCAS, immediately prior to the Merger, CRG has agreed to convert $5,812,323.91 of the CRG Interest into common stock of Valeritas, at a price equal to $1.25
per share, which would result in Valeritas issuing 4,649,859 shares of common stock of Valeritas to CRG, and CRG and WCAS have agreed to convert $10,762,280.21 of the CRG Interest and $2,075,662.72 of the WCAS Interest into shares of Series AB
Preferred Stock of Valeritas, at a price equal to $1.25 per share, which would result in Valeritas issuing 8,609,824 and 1,660,530 shares of Series AB Preferred Stock to CRG and WCAS, respectively. Thereafter, upon the closing of the Merger, the
shares of Series AB Preferred Stock will be exchanged for stock in the Company and all common stock and preferred stock of Valeritas will be cancelled for no consideration. Each share of Series AB Preferred Stock outstanding immediately prior to the
Closing Date will be converted into the right to receive 0.23856 shares of Company common stock. 
 The outstanding principal indebtedness held by CRG under
the Term Loan Agreement will remain outstanding following the Merger in accordance with the following terms (the “Revised Term Loan”): 
  

	 	•	 	The amount of the Revised Term Loan shall be the current $50.0 million outstanding principal indebtedness. 

  

	 	•	 	The Revised Term Loan shall mature on the twentieth (20th) quarterly payment date following the closing date of the Merger (the “Maturity Date”). Principal, inclusive of all accrued paid-in-kind
interest, on the Revised Term Loan will amortize in a single bullet payment on the Maturity Date. 

  

	 	•	 	Interest on the Revised Term Loan will accrue at a rate of eleven percent (11%) per annum paid quarterly (on March 31, June 30, September 30, and December 31). Interest shall be payable, at the Company’s option, as
eight percent (8%) cash interest and three percent (3%) paid in-kind interest; provided, however, that before the eighth (8th) quarterly payment date, interest shall be payable, at the
Company’s option, in its entirety as paid-in-kind interest. All cash interest shall otherwise be paid quarterly. During any period in which an event of default has occurred and is continuing, the interest rate shall increase by four percent
(4%) per annum and be payable entirely in cash. 

  

	 	•	 	The Revised Term Loan shall be secured by a first priority security interest and right of payment in all of the Company’s global assets, accounts and proceeds now existing or to be acquired. The Revised Term Loan
shall be guaranteed on a secured basis by the Company. 

	 	•	 	To permit the Merger, all existing defaults under the Term Loan Agreement shall be permanently waived. 

  

	 	•	 	The Company may, at its option, repay the Revised Term Loan in whole or in part without any penalty or prepayment fees. 

  

	 	•	 	The Revised Term Loan includes only one operating covenant, which requires that the Company maintains an end-of-day cash balance greater than $5 million. The only other covenants are those usual and customary for
this type of transaction. 

 The outstanding principal indebtedness held by WCAS under the WCAS Note will remain outstanding following the
Merger in accordance with the following terms (the “Amended WCAS Note”): 
  

	 	•	 	The Amended WCAS Note will mature on September 8, 2021 (the “WCAS Note Maturity Date”). Principal, inclusive of all accrued paid-in-kind interest, on the Amended WCAS Note will amortize in a single
bullet payment on the WCAS Note Maturity Date. 

  

	 	•	 	The Amended WCAS Note shall accrue interest at a rate of ten percent (10%) per annum payable entirely as paid-in-kind interest. 

  

	 	•	 	WCAS’s right to payment under the Amended WCAS Note shall be subject to CRG’s payment of the Revised Term Loan pursuant to a subordination agreement by and between WCAS and CRG. 

 

	 	•	 	To permit the Merger, all existing defaults under the WCAS Note shall be permanently waived. 

 Schedule 4c(iv) 

Agreements to Register Securities 
 None.

 Schedule 4c(vi) 

Anti-Dilution Rights 
 None. 

 Schedule 4e 

Required Notices and Consents 
 None. 

 Schedule 4f 

Litigation 
 None. 

 Schedule 4k 

Intellectual Property 
 The Company has
been unable to locate the assignments to BioValve Technologies, Inc. for the following expired provisional patent applications, although all inventor assignments have been obtained with respect to all issued patents: 

 

			
	 Application Number
	  	 Inventor Name

	60/250,409	  	Peter F. Marshall
	60/250,927	  	Peter F. Marshall
	60/250,408	  	Peter F. Marshall
	60/250,403	  	Peter F. Marshall
	60/250,422	  	Peter F. Marshall
	60/250,413	  	Peter F. Marshall

 Schedule 4n 

Title to Personal Property and Assets 

The Revised Term Loan shall be secured by a first priority security interest and right of payment in all of the Company’s global assets, accounts and
proceeds now existing or to be acquired. The Revised Term Loan shall be guaranteed on a secured basis by the Company. 

 Schedule 4r 

Rights of First Refusal 
 None. 

 EXHIBIT A 

FORM OF REGISTRATION RIGHTS AGREEMENT 

 EXHIBIT B 

LOCK-UP AGREEMENT SIGNATORIES 
  

	 	•	 	Capital Royalty Partners II L.P. 

  

	 	•	 	Capital Royalty Partners II - Parallel Fund “A” L.P. 

  

	 	•	 	Parallel Investment Opportunities Partners II L.P. 

  

	 	•	 	Capital Royalty Partners II – Parallel Fund “B” (Cayman) L.P. 

  

	 	•	 	Capital Royalty Partners II (Cayman) L.P. 

  

	 	•	 	John Timberlake 

  

	 	•	 	Mark Conley 

  

	 	•	 	Geoff Jenkins 

  

	 	•	 	Matthew Nguyen 

  

	 	•	 	Montrose Capital Limited 

 EXHIBIT C 

FORM OF LOCK-UP AGREEMENTEX-10.5

 Exhibit 10.5 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE
SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT
REQUIRED UNDER SUCH ACT OR UNLESS SOLD IN ACCORDANCE WITH RULE 144 UNDER SUCH ACT. 
  

			
	WARRANT NO. 2016-[            ]	  	NUMBER OF SHARES: [                ]
	DATE OF ISSUANCE: [            ], 2016	  	(subject to adjustment hereunder)
	EXPIRATION DATE: [            ], 2021	  	

 WARRANT TO PURCHASE SHARES 

OF COMMON STOCK OF 
 VALERITAS
HOLDINGS, INC. 
 This Warrant is issued to [            ], or its registered
assigns (including any successors or assigns, the “Warrantholder”), in connection with that certain Subscription Agreement, dated as of [            ], 2016, by and among
Valeritas Holdings, Inc. (f/k/a Cleaner Yoga Mat, Inc.), a Delaware corporation (the “Company”), and each of those persons and entities listed as a Purchaser on Annex A thereto (the “Purchase
Agreement”). 
 1. EXERCISE OF WARRANT. 

(a) Number and Exercise Price of Warrant Shares; Expiration Date. Subject to the terms and conditions set forth herein and set forth in
the Purchase Agreement, the Warrantholder is entitled to purchase from the Company up to [                ] shares of the Company’s Common Stock,
$[        ] par value per share (the “Common Stock”) (as adjusted from time to time pursuant to the provisions of this Warrant) (the “Warrant Shares”), at a purchase price of
$5.00 per share (the “Exercise Price”), on or before 5:00 p.m. New York City time on [            ], 2021 (the “Expiration Date”) (subject to earlier
termination of this Warrant as set forth herein). 
 (b) Method of Exercise. While this Warrant remains outstanding and
exercisable in accordance with Section 1(a) above, the Warrantholder may exercise this Warrant in accordance with Section 5 herein, by either: 

(1) wire transfer to the Company or cashier’s check drawn on a United States bank made payable to the order of the Company, or 

(2) exercising of the right to credit the Exercise Price against the Fair Market Value of the Warrant Shares (as defined below) at the time
of exercise (the “Net Exercise”) pursuant to Section 1(c). 

 Notwithstanding anything herein to the contrary, the Warrantholder shall not be required to
physically surrender this Warrant to the Company until the Warrantholder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Warrantholder shall surrender this Warrant to the
Company for cancellation within three (3) trading days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Warrantholder and the Company shall maintain records showing the
number of Warrant Shares purchased and the date of such purchases. 
 (c) Net Exercise. If the Company shall receive written notice
from the Warrantholder at the time of exercise of this Warrant that the holder elects to Net Exercise the Warrant, the Company shall deliver to such Warrantholder (without payment by the Warrantholder of any exercise price in cash) that number of
Warrant Shares computed using the following formula:  
  

			
	X =	 	 Y (A - B) 
	 	        A

 Where 
  

					
	X	 	=	  	The number of Warrant Shares to be issued to the Warrantholder.
			
	Y	 	=	  	The number of Warrant Shares purchasable under this Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being cancelled (at the date of such calculation).
			
	A	 	=	  	The Fair Market Value of one (1) share of Common Stock on the trading date immediately preceding the date on which Warrantholder elects to exercise this Warrant.
			
	B	 	=	  	The Exercise Price (as adjusted hereunder).

 The “Fair Market Value” of one share of Common Stock shall mean (x) the last reported sale
price and, if there are no sales, the last reported bid price, of the Common Stock on the business day prior to the date of exercise on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg Financial Markets
(or a comparable reporting service of national reputation selected by the Company and reasonably acceptable to the holder if Bloomberg Financial Markets is not then reporting sales prices of the Common Stock) (collectively,
“Bloomberg”), (y) if the foregoing does not apply, the last sales price of the Common Stock in the over-the-counter market on the pink sheets or bulletin board for such security as reported by Bloomberg, and, if there are no sales,
the last reported bid price of the Common Stock as reported by Bloomberg or, (z) if fair market value cannot be calculated as of such date on either of the foregoing bases, the price determined in good faith by the Company’s Board of Directors.

  
 -2- 

 “OTC Markets” shall mean either OTC QX or OTC QB of the OTC Markets Group, Inc.

 “Trading Market” shall mean any of the following markets or exchanges on which the Common Stock is listed or quoted for
trading on the date in question: the NYSE MKT, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the New York Stock Exchange or the OTC Markets (or any successors to any of the foregoing). 

(d) Deemed Exercise. In the event that immediately prior to the close of business on the Expiration Date, the Fair Market Value of
one share of Common Stock (as determined in accordance with Section 1(c) above) is greater than the then applicable Exercise Price, this Warrant shall be deemed to be automatically exercised on a net exercise issue basis pursuant to
Section 1(c) above, and the Company shall deliver the applicable number of Warrant Shares to the Warrantholder pursuant to the provisions of Section 1(c) above and this Section 1(d). 

2. CERTAIN ADJUSTMENTS. 
 (a)
Adjustment of Number of Warrant Shares and Exercise Price. The number and kind of Warrant Shares purchasable upon exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows: 

(1) Subdivisions, Combinations and Other Issuances. If the Company shall at any time after the Date of Issuance but prior to the
Expiration Date subdivide its shares of capital stock of the same class as the Warrant Shares, by split-up or otherwise, or combine such shares of capital stock, or issue additional shares of capital stock as a dividend with respect to any shares of
such capital stock, the number of Warrant Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a
combination. Appropriate adjustments shall also be made to the Exercise Price payable per share, but the aggregate Exercise Price payable for the total number of Warrant Shares purchasable under this Warrant (as adjusted) shall remain the
same. Any adjustment under this Section 2(a)(1) shall become effective at the close of business on the date the subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no record date
is fixed, upon the making of such dividend. 
 (2) Reclassification, Reorganizations and Consolidation. In case of any
reclassification, capital reorganization or change in the capital stock of the Company (other than as a result of a subdivision, combination or stock dividend provided for in Section 2(a)(1) above) that occurs after the Date of Issuance,
then, as a condition of such reclassification, reorganization or change, lawful provision shall be made, and duly executed documents evidencing the same from the Company or its successor shall be delivered to the Warrantholder, so that the
Warrantholder shall thereafter have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of stock and/or other securities
or property (including, if applicable, cash) receivable in connection with such reclassification, reorganization or change by a holder of the same number and type of securities as were purchasable as Warrant Shares by the Warrantholders immediately
prior to such reclassification, reorganization or change. In any such case appropriate provisions shall be made with respect to the rights and interest of the 

  
 -3- 

 
Warrantholder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities or property deliverable upon exercise hereof, and appropriate
adjustments shall be made to the Exercise Price payable hereunder, provided the aggregate Exercise Price shall remain the same (and, for the avoidance of doubt, this Warrant shall be exclusively exercisable for such shares of stock and/or other
securities or property from and after the consummation of such reclassification or other change in the capital stock of the Company). 

(3) Adjustment of Exercise Price Upon Subsequent Equity Sales. In the event the Company shall at any time after the original issuance
date of this Warrant make any issuance, sale, grant of any option or right to purchase or other disposition of any equity security or any equity-linked or related security (including, without limitation, any “equity security” as that term
is defined under Rule 405 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), any securities convertible into Additional Shares of Common Stock (as such term is defined in the Purchase Agreement)
(the “Additional Securities”), for a consideration per share that is less than the Exercise Price (adjusted for stock splits, combinations, dividends and the like occurring after the date hereof) (the foregoing, a “Dilutive
Issuance”), then the then Exercise Price shall be reduced, concurrently with such Dilutive Issuance, to a price (calculated to the nearest cent) determined in accordance with the following formula: 

 

	
	CP2 = CP1* (A + B) ÷ (A + C).

 For purposes of the foregoing formula, the following definitions shall apply: 

(1) “CP2” shall mean the Exercise Price in effect immediately after such issuance of Additional Securities; 

(2) “CP1” shall mean the Exercise Price in effect immediately prior to such issuance of Additional Securities; 

(3) “A” shall mean the number of shares of Common Stock outstanding immediately prior to such issuance of Additional
Securities (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of the Company’s convertible securities outstanding immediately prior to such issuance or upon conversion or exchange of convertible
securities (including the Warrants) outstanding (assuming exercise of any outstanding convertible securities therefor) immediately prior to such issuance); 

(4) “B” shall mean the number of shares of Common Stock that would have been issued if such Additional Securities had been
issued at a price per share equal to CP1 (determined by dividing the aggregate consideration received by the Company in respect of such issuance by CP1); and 

(5) “C” shall mean the number of such Additional Securities issued in such transaction. 

(b) Notice to Warrantholder. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe 

  
 -4- 

 
for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Change of
Control or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then the Company shall deliver to the Warrantholder a notice of such transaction at least ten (10) business days prior to the
applicable record or effective date on which a person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not
affect the validity of the corporate action required to be described in such notice. 
 (c) Calculations. All calculations under this
Section 2 shall be made to the nearest cent or the nearest whole share, as the case may be. For purposes of this Section 2, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the
sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding. 
 (d) Treatment of Warrant upon
a Change of Control.
 (1) If, at any time while this Warrant is outstanding, the Company consummates a Change of Control, then a
holder shall have the right thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Change of Control if it had been,
immediately prior to such Change of Control, a holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant (the “Alternate Consideration”). The Company shall not effect any such Change of Control
unless prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or the corporation purchasing or otherwise acquiring such assets or other appropriate corporation or entity shall assume the obligation
to deliver to the holder, such Alternate Consideration as, in accordance with the foregoing provisions, the holder may be entitled to purchase, and the other obligations under this Warrant. 

(2) As used in this Warrant, a “Change of Control” shall mean (i) a merger or consolidation of the Company with another
corporation (other than a merger effected exclusively for the purpose of changing the domicile of the Company), (ii) the sale, assignment, transfer, conveyance or other disposal of all or substantially all of the properties or assets or all or a
majority of the outstanding voting shares of capital stock of the Company, (iii) a purchase, tender or exchange offer accepted by the holders of a majority of the outstanding voting shares of capital stock of the Company, or (iv) a
“person” or “group” (as these terms are used for purposes of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) is or shall become the “beneficial owner”
(as defined in Rule 13d-3 under the Exchange Act), directly or indirectly at least a majority of the voting power of the capital stock of the Company. 

3. NO FRACTIONAL SHARES. No fractional Warrant Shares or scrip representing fractional shares will be issued upon exercise of this
Warrant. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the Fair Market Value of one Warrant Share. 

  
 -5- 

 4. NO STOCKHOLDER RIGHTS. Until the exercise of this Warrant or any portion of this Warrant,
the Warrantholder shall not have, nor exercise, any rights as a stockholder of the Company (including without limitation the right to notification of stockholder meetings or the right to receive any notice or other communication concerning the
business and affairs of the Company) except as provided in Section 8 below. 
 5. MECHANICS OF EXERCISE.

(a) Delivery of Warrant Shares Upon Exercise. This Warrant may be exercised by the holder hereof, in whole or in part, by
delivering to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Warrantholder at the address of the Warrantholder appearing on the books of the Company) of a duly executed copy of
the Notice of Exercise in the form attached hereto as Exhibit A by facsimile or e-mail attachment and paying the Exercise Price (unless the Warrantholder has elected to Net Exercise) then in effect with respect to the number of Warrant Shares
as to which the Warrant is being exercised. This Warrant shall be deemed to have been exercised immediately prior to the close of business on the date of the delivery to the Company of the Notice of Exercise as provided above, and the person
entitled to receive the Warrant Shares issuable upon such exercise shall be treated for all purposes as the holder of such shares of record as of the close of business on such date. Warrant Shares purchased hereunder shall be transmitted by the
Company’s transfer agent to the holder by crediting the account of the holder’s prime broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a
participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the holder or (B) the shares are eligible for resale by the holder without
volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery to the address specified by the holder in the Notice of Exercise by the end of the day on the date that is three (3) trading days from the delivery to the
Company of the Notice of Exercise and payment of the aggregate Exercise Price (unless exercised by means of a cashless exercise pursuant to Section 1(c)). The Warrant Shares shall be deemed to have been issued, and the holder or any
other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by Net Exercise)
and all taxes required to be paid by the holder, if any, prior to the issuance of such shares, having been paid. 
 (b) Rescission
Rights. If the Company fails to cause the transfer agent to transmit to the Warrantholder the Warrant Shares pursuant to Section 5(a) by the Warrant Share Delivery Date, then the Warrantholder will have the right to rescind such exercise.

 (c) Warrantholder’s Exercise Limitations. A holder shall not have the right to exercise this Warrant,
pursuant to Section 1 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the holder (together with the holder’s affiliates, and any other persons acting
as a group together with the holder or any of the holder’s affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the aggregate number of shares of
Common Stock beneficially owned by the holder and its affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which 

  
 -6- 

 
such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the holder or any of its affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other convertible notes or convertible
preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the holder or any of its affiliates. Except as set forth in the preceding sentence, for purposes
of this section, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the holder that the Company is not representing to the
holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this
Section 5(c) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the holder together with any affiliates) and of which portion of this Warrant is exercisable shall be in the sole
discretion of the holder, and the submission of a Notice of Exercise shall be deemed to be the holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the holder together with any affiliates) and
of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercise
of the Warrant that are not in compliance with the Beneficial Ownership Limitation. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder. For purposes of this Section 5(c), in determining the number of outstanding shares of Common Stock, a holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the
Company’s most recent periodic or annual report filed with the U.S. Securities and Exchange Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the
Company’s transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of a holder, the Company shall within two (2) trading days confirm in writing to the holder the number of shares of Common
Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the holder or its affiliates
since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock issuable upon exercise of this Warrant. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be
construed and implemented in strict conformity with the terms of this Section 5(c) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or
to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. 

6. CERTIFICATE OF ADJUSTMENT. Whenever the Exercise Price or number or type of securities issuable upon exercise of this Warrant is
adjusted, as herein provided, the Company shall, at its expense, promptly deliver to the Warrantholder a certificate of an officer of the Company setting forth the nature of such adjustment and showing in detail the facts upon which such adjustment
is based. 

  
 -7- 

 7. COMPLIANCE WITH SECURITIES LAWS. 

(a) The Warrantholder understands that this Warrant and the Warrant Shares are characterized as “restricted securities” under the
federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations this Warrant and the Warrant Shares may be resold without registration
under the Securities Act only in certain limited circumstances. In this connection, the Warrantholder represents that it is familiar with Rule 144 under the Securities Act, as presently in effect, and understands the resale limitations imposed
thereby and by the Securities Act. 
 (b) Prior and as a condition to the sale or transfer of the Warrant Shares issuable upon exercise of
this Warrant, the Warrantholder shall furnish to the Company such certificates, representations, agreements and other information, including an opinion of counsel, as the Company or the Company’s transfer agent reasonably may require to confirm
that such sale or transfer is being made pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, unless such Warrant Shares are being sold or transferred pursuant to an effective
registration statement. 
 (c) The Warrantholder acknowledges that the Company may place a restrictive legend on the Warrant Shares issuable
upon exercise of this Warrant in order to comply with applicable securities laws, in substantially the following form and substance, unless such Warrant Shares are otherwise freely tradable under Rule 144 of the Securities Act: 

“THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST
OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A TRANSACTION WHICH IS
EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION OF
COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER APPLICABLE LAWS.” 

  
 -8- 

 8. REPLACEMENT OF WARRANTS. On receipt of evidence reasonably satisfactory to the Company of
the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of
any such mutilation, on surrender and cancellation of such Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor. 

9. NO IMPAIRMENT. Except to the extent as may be waived by the holder of this Warrant, the Company will not, by amendment of its charter
or through a Change of Control, dissolution, sale of assets or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of
all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment. 

10. TRADING DAYS. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall be other than a day on which the Common Stock is traded on the Trading Market, then such action may be taken or such right may be exercised on the next succeeding day on which the Common Stock is so traded. 

11. TRANSFERS; EXCHANGES.
 (a)
Subject to compliance with applicable federal and state securities laws and Section 7 hereof, this Warrant may be transferred by the Warrantholder to any Affiliate (as defined below) with respect to any or all of the Warrant Shares
purchasable hereunder (a “Permitted Transfer”). For a transfer of this Warrant as an entirety by the Warrantholder, upon surrender of this Warrant to the Company, together with the Notice of Assignment in the form attached hereto as
Exhibit B duly completed and executed on behalf of the Warrantholder, the Company shall issue a new Warrant of the same denomination to the assignee. For a transfer of this Warrant with respect to a portion of the Warrant Shares
purchasable hereunder, upon surrender of this Warrant to the Company, together with the Notice of Assignment in the form attached hereto as Exhibit B duly completed and executed on behalf of the Warrantholder, the Company shall issue a new
Warrant to the assignee, in such denomination as shall be requested by the Warrantholder, and shall issue to the Warrantholder a new Warrant covering the number of shares in respect of which this Warrant shall not have been transferred. The term
“Affiliate” as used herein means, with respect to any person, any other person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such person, and any
officers, employees or partners of the Warrantholder. 
 (b) Upon any Permitted Transfer, this Warrant is exchangeable, without expense, at
the option of the Warrantholder, upon presentation and surrender hereof to the Company for other warrants of different denominations entitling the holder thereof to purchase in the aggregate the same number of shares of Common Stock purchasable
hereunder. This Warrant may be divided or combined with other warrants that carry the same rights upon presentation hereof at the principal office of the Company together with a written notice specifying the

  
 -9- 

 
denominations in which new warrants are to be issued to the Warrantholder and signed by the Warrantholder hereof. The term “Warrants” as used herein includes any warrants into
which this Warrant may be divided or exchanged. 
 12. AUTHORIZED SHARES. The Company covenants that, during the period the Warrant is
outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take
all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
quoted or listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such
Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue). 
 14. MISCELLANEOUS.

(a) This Agreement shall be governed by and construed in accordance with the laws of the United States of America and the State of New York,
both substantive and remedial, without regard to New York conflicts of law principles. Any judicial proceeding brought under this Agreement or any dispute arising out of this Agreement or any matter related hereto shall be brought in the courts
of the State of New York, New York County, or in the United States District Court for the Southern District of New York. 
 (b) All notices,
requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed facsimile or electronic mail, or mailed by first-class registered or certified airmail, or nationally recognized overnight express courier, postage
prepaid, and shall be deemed given when so sent in the case of facsimile or electronic mail transmission, or when so received in the case of mail or courier, and addressed as follows: (a) if to the Company, at 750 Route 202 South, Suite 600,
Bridgewater, NJ 08807, Attention: Chief Executive Officer, Facsimile: (908) 927-9927, Email: jtimberlake@valeritas.com; with a copy to (which shall not constitute notice) Morgan, Lewis & Bockius LLP, 502 Carnegie Center, Princeton, NJ
08540-6241, Attention: Emilio Ragosa, Esq., Facsimile: (609) 919-6701, E-Mail: emilio.ragosa@morganlewis.com; and (b) if to the Warrantholder, at such address or addresses (including copies to counsel) as may have been furnished by the Warrantholder
to the Company in writing. 
 (c) The invalidity or unenforceability of any provision hereof shall in no way affect the validity or
enforceability of any other provisions. 
 [Signature Page Follows] 

  
 -10- 

 IN WITNESS WHEREOF, this Common Stock Purchase Warrant is issued effective as of the date first
set forth above. 
  

			
	VALERITAS HOLDINGS, INC.
		
	By:	 	  

	Name:	 	John Timberlake
	Title:	 	Chief Executive Officer

 [Signature Page to Warrant No. 2016-[    ]] 

 EXHIBIT A 

NOTICE OF EXERCISE 
 (To be signed
only upon exercise of Warrant) 
 To: Valeritas Holdings, Inc. 

The undersigned, the Warrantholder of the attached Warrant, hereby irrevocably elects to exercise the purchase right represented by such
Warrant for, and to purchase thereunder,                      (            ) shares of
Common Stock of Valeritas Holdings, Inc. and (choose one) 
          herewith makes payment of
                     Dollars ($        ) thereof 

or 

         elects to Net Exercise the Warrant pursuant to Section 1(b)(2) thereof. 

The undersigned requests that the certificates or book entry position evidencing the shares to be acquired pursuant to such exercise be issued
in the name of, and delivered to
                                        , whose
address is
                                        
                    . 
 By its
signature below the undersigned hereby represents and warrants that it is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended, and agrees to be bound by the terms and
conditions of the attached Warrant as of the date hereof, including Section 7 thereof. 
  

									
	DATED:	 	  
	 		 	
				
		 		 		 	(Signature must conform in all respects to name of the Warrantholder as specified on the face of the Warrant)
				
		 		 		 	  

		 		 		 	[                    ]
		 		 		 	Address:	 	  

		 		 		 	  

		 		 		 	  

 EXHIBIT B 

NOTICE OF ASSIGNMENT FORM 
 FOR
VALUE RECEIVED, [                    ] (the “Assignor”) hereby sells, assigns and transfers all of the rights of the undersigned
Assignor under the attached Warrant with respect to the number of shares of common stock of Valeritas Holdings, Inc. (the “Company”) covered thereby set forth below, to the following “Assignee” and, in connection
with such transfer, represents and warrants to the Company that the transfer is in compliance with Section 7 of the Warrant and applicable federal and state securities laws: 

 

			
	NAME OF ASSIGNEE
		
	Number of shares:	  	  

			
		
	Dated:	  	  

 

			
	ADDRESS/FAX NUMBER

  

 

			
		
	Signature:	  	  

			
		
	Witness:	  	  

 
 

  
 ASSIGNEE ACKNOWLEDGMENT

 The undersigned Assignee acknowledges that it has reviewed the attached Warrant and by its signature below it hereby represents and
warrants that it is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended, and agrees to be bound by the terms and conditions of the Warrant as of the date hereof,
including Section 7 thereof. 
  

			
	Signature:	 	  

 
			
		
	By:	 	  

	Its:	 	  

  

	
	Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]